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Preface
The mitochondrion is a unique and ubiquitous organelle that contains its own 
genome, encoding essential proteins that are major components of the respiratory 
chain and energy production system. It is reasonable therefore that mitochondria 
play a dominant role in the life and function of eukaryotic cells including neurons 
and glia, as their survival and activity depend almost exclusively upon mitochondrial 
energy production and supply.
Thus, mitochondrial functional impairment is related to a substantial number of 
neurological disorders, most of them having high incidence in the range of neuro-
degenerative diseases, such as Parkinson’s disease, Alzheimer’s disease, Friedreich’s 
ataxia, and Huntington’s disease.
New techniques improving mitochondrial DNA analysis and detecting mutation 
penetrance patterns have also increased the awareness of the rate of mitochondrial 
involvement in the pathogenetic mechanisms of a substantial number of neurologi-
cal diseases. In addition, since mitochondria synthesize ATP through oxidative 
phosphorylation (OXPHOS) as the main energy providers for neurons and glia, 
their dysfunction induces an energy crisis with tragic consequences for cells of high 
energy demands.
Besides energy production, mitochondria also play a vital role in neuronal and 
glial calcium homeostasis due to their high capacity for accumulating Ca2+. On the 
other hand, mitochondria comprise reactive oxygen species (ROS), which control 
redox status, intracellular Ca2+ levels, and may induce apoptosis by activating the 
mitochondrial permeability transition pore (mtPTP), a crucial point of excitotoxic 
neuronal injury.
In a parallel manner, ROS may play an important role in inflammatory conditions 
of the brain such as Multiple Sclerosis (MS) either by decreased activity of mito-
chondrial enzymes, or by peroxidation of lipids, proteolipid protein or myelin basic 
protein, therefore destabilizing the anoxic myelin sheath.
In reality, the role of the mitochondria in neuronal survival and function is multi-
dimensional. Thus metabolic intermediates derived from Krebs cycle in the mito-
chondria may behave as co-factors for epigenetic modifications, playing an essential 
role in histone acetylation and in the addition and removal of epigenetic marks, 
controlling the expression of a substantial number of genes in the neuronal genome. 
Mitochondria also contribute to the synthesis of steroid hormones such as glucocor-
ticoids, mineralocorticoids, progestogens, estrogens, and androgens; and facilitate 
the interaction of catecholamines with their receptors, therefore promoting neuro-
nal plasticity by stress mediators. Thyroid hormones also stimulate mitochondrial 
activity by enhancing oxidative phosphorylation. In turn, steroid hormones regu-
late mitochondrial respiratory capacity and oxidative stress, since mitochondria 
are particularly sensitive and dependable on hormonal stimulation. Given that 
sex hormones regulate mitochondrial biogenesis and function, it is expected that 
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mitochondria express sexual dimorphism and show different reactions to stress and 
disease in males and females.
Mitochondria modulate systemic energy homeostasis in both sexes by the produc-
tion and release of mitokines, such as humanin, and by operating as the central 
organelle of adaptation and stress-response modulation.
From the morphological point of view, mitochondrial alterations are accurately 
visualized in light microscopy in a properly fixed material by means of a number of 
special staining reactions. Transmission electron microscopy has also contributed 
substantially in the morphological study of mitochondria in neurological diseases 
revealing the disruption of the cristae and the disarrangement of their inner 
architecture, taking in consideration also that mitochondria exhibit high morpho-
logical variability according to activity and metabolic demands of the cell. Using 
transmission electron microscopy, it was also observed that in Alzheimer’s disease, 
mitochondrial cristae are disrupted from the initial stages of the disease even in 
areas of the brain with minimal Alzheimer’s pathology.
A considerable number of syndromes have been described with marked neurologi-
cal phenomena in the spectrum of mitochondrial disorders. It must be highlighted 
that the severity of the clinical manifestation of mitochondrial dysfunction varies 
considerably, given the threshold in the degree of mitochondrial deficiency for the 
clinical expression of the disease. Thus, the symptoms and clinical phenomena are 
continuously aggravated, in the majority of the cases of mitochondrial diseases, 
as the age of the patient advances and the energy deficiency increases in various 
organs. However, the most frequent clinical manifestations that have been reported 
in mitochondrial diseases include cognitive impairment, epilepsy, myopathies, 
renal and liver dysfunction, cardiopathy and disorders of inner secretion resulting 
in hormonal imbalance.
Molecular genetic testing and muscle biopsy for histochemical investigation in light 
microscopy and ultrastructural study of the specimens in electron microscopy are 
essential diagnostic procedures for the documentation and final verification of the 
diagnosis of mitochondrial disorders. In addition, biochemical testing in blood, 
urine, and spinal fluid associated with neuroimaging would be useful diagnostic 
procedures in following up the progression of mitochondrial diseases.
A final escape from the labyrinth of mitochondrial related neurological disorders 
is extremely difficult and less pragmatic under the present circumstances. Thus 
the treatment for the majority of mitochondrial diseases remains mostly symp-
tomatic. Therapeutic factors enhancing mitochondrial biogenesis and restoring 
nitric oxide production might be beneficial at the initial stages of the diseases. 
The administration of cardiolipin protector and agents aiming at ameliorating 
mitochondrial function, such as antioxidants, riboflavin, idebenone, CoQ10 
(ubiquinone) and thiamin might be reasonably prescribed in attempting to 
improve the physical and mental condition of the patients who suffer from 
mitochondrial disorders.
Prospectively, an efficient treatment could be based on a stable modulation of 
mtDNA heteroplasmy, whereas gene therapy, liver transplantation, gene transfer 
and tRNA-targeted therapeutic attempts as well as stem cell therapy for nuclear 
DNA mutations are promising therapeutic endeavors.
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In conclusion, an efficient and easy treatment of mitochondrial dysfunction would 
open new bright horizons in the therapy of inflammatory and neurodegenerative 
disorders, being beneficial in the amelioration of the quality of life of a substantial 
number of patients.
In this book, the authors attempted to describe the complex relationship of mito-
chondrial disorders with neurodegeneration for  further clarification and analysis 
of the multidimensional background of the pathogenetic mechanisms of neurologi-
cal diseases.
















Mitochondria (from Greek mito, μίτος, thread; and chondrion, χόνδριον, thick 
granule) are principal cell organelles, which participate in a wide spectrum of 
essential cellular functions, being the main energy providers for living eukaryotic 
cells, especially for neurons and glia, which are characterized by high metabolic 
activity and energy consumption.
Thus, it is expectable that mitochondrial dysfunction, having pleotropic effect 
on the cell, may play a crucial role in a substantial number of serious neurological 
disorders including Alzheimer’s disease (AD) [1, 2], Parkinson’s disease (PD) [3] 
Huntington’s disease [4, 5], amyotrophic lateral sclerosis (ALS) [6], multiple sclero-
sis (MS) [7, 8], as well as some of the major psychiatric diseases [9], given that both, 
neurons and glia, are particularly sensitive and vulnerable to energy decline [10].
Mitochondria hypothesis of those devastating diseases advocates reasonably 
in favor of the important role that mitochondrial dysfunction may play in the 
early stages of neurodegeneration by inducing energy deficiency and oxidative 
stress [11].
However, the majority of the mitochondrial diseases, being maternally inher-
ited, which are designated as mitochondrial encephalomyopathies [12], are closely 
connected either with the impairment of nucleus-to-mitochondria signaling or with 
mutations in mtDNA or nuclear genome that affect seriously the mitochondrial 
respiratory function even from the initial steps of the life [13], inducing defective 
oxidative phosphorylation (OXPHOS).
2. The genetic background of mitochondrial dysfunction
It is well known that mitochondria, as very specific organelles, include several 
copies (2–10 copies) of their own DNA (mtDNA), which consists of a 16.5 kb 
circular DNA molecule, being particularly prone to mutation [14]. mtDNA encodes 
for 37 genes, 13 of them encoding 13 polypeptides, which all are major components 
of OXPHOS complexes I, III, IV, and V, along with 22 tRNAs and 2 rRNAs, which 
play an essential role for the expression of the 13 subunits [15].
Mutations in mtDNA may be related to 25% of childhood-onset diseases [16] 
and to 75% of adult-onset ones [17], depending on the existing homoplasmy or 
heteroplasmy. In addition, the accumulation of mtDNA mutations can also induce 
or facilitate the aging process [18], since a common phenomenon in mammalian 
aging is the substantial decrease of electron transfer in mitochondria [19, 20].
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3. Biological consequences of mitochondrial dysfunction
The mitochondria in addition to energy production compose also reactive 
oxygen species (ROS), which control redox status and intracellular Ca2+ levels and 
may induce apoptosis, by activating the mitochondrial permeability transition pore 
(mtPTP) [21]. In addition, mitochondria play a very important role in neuronal and 
glial calcium homeostasis due to their high capacity to accumulating Ca2+ [22].
Resting neurons contain usually minimal Ca2+ that can be increased by the 
activation of NMDA glutamate receptors, which induce a massive entry of Ca2+ into 
neurons, resulting in its high accumulation in the mitochondria [23]. Continuous 
activation of NMDA receptors would therefore induce Ca2+ overload of the mito-
chondria with the tragic consequence of the cell apoptosis, which frequently occurs 
as an epilogue of the excitotoxicity [24].
The apoptosis consists of a wide spectrum of biological phenomena [25] 
 including the release of caspase activators [26], the alterations of the electron 
transport system, the change of mitochondrial transmembrane potential, the 
disruption of the cellular oxidation-reduction equilibrium, and the activation of 
the pro-apoptotic Bcl-2 family proteins [27, 28].
In the majority of the mitochondria-related neurological disorders, the 
functional or morphological alteration of the mitochondrial may be induced by 
increased ROS production, abnormal protein aggregates (Ab, tau) [29, 30], muta-
tions in genes encoded by the mitochondrial and nuclear genome, and exposure of 
the cell to toxic factors [31].
4. The morphology of mitochondria in health and disease
Cell mitochondria could be visualized in light microscopy in properly fixed 
material by means of a number of special staining reactions [32–34]. It is observed 
that their size generally ranges from 0.5 to 1 micron in diameter, being changeable 
due to frequent divisions and fusions, which are controlled by mitofusin activity 
[35]. The shape of the mitochondria is also continuously changed due to their 
impressive active motility, controlled by calcium signal [36, 37], given that they 
are in constant flux, especially in brain’s areas of high energy consumption in 
order to contribute in energy supply and to participate in the intracellular signal-
ing actively [38].
Electron microscopy has been contributing greatly in the study of mitochondria 
in health and disease [39, 40]. Each mitochondrion in healthy condition is sur-
rounded by a limiting double membrane and includes numerous longitudinal or 
tubular invaginations called mitochondrial cristae that are folds of the inner layer of 
the double membrane [41], which is four times greater than the outer one.
The cristae are mostly arranged perpendicularly to the long axis of the organelle, 
exhibiting a high morphological variability according to metabolic demands of the 
cell [42], being frequently lamellar, tubular, or triangle-shaped. In the majority of 
the mitochondria, the cristae are arranged parallel to one another inside a structure-
less matrix, which is clearly seen among the cristae.
Cardiolipin seems to play a crucial role in the morphology of cristae, since the 
disruption of cardiolipin biosynthesis induces obvious alteration of the cristae 
morphology [43]. In addition, Opa1, which is a GTPase, demonstrating dynamin-
like properties, plays a substantial role in the modulation of the cristae structure 
and in their remodeling during mitochondrial fusion and fission [44] and apoptotic 
process [45]. The cristae have a high protein content [46], being also the principal 
site of the oxidative phosphorylation [47].
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Electron microscope tomography, revealing the three-dimensional appearance 
of the cristae, shows that they are connected with the inner mitochondrial mem-
brane by a narrow, tubular opening, characterized as “crista junction” (CJ), which 
is associated with protein import [48] and mitochondrial inner compartmentaliza-
tion [49].
In neurodegeneration such as in Alzheimer’s disease, mitochondrial cristae are 
disrupted even from the initial stages of the disease, and concentric patterns of 
cristae membranes are frequently seen [50].
5. Mitochondrial trafficking and concentration
Mitochondria, like many other cell organelles, are oriented and positioned prop-
erly in neurons and glia in order to be able to fulfill the energy demands of the cells 
perpetually. Thus, neurons, axons, dendrites, and synapses, which are character-
ized by high ceaseless activity, have intensive mitochondrial motility and impressive 
concentrations [51], via various trafficking patterns [52].
Axonal transport of mitochondria [53] requires microtubules (MTs) [54, 55] or 
actin filaments in axons [56], which facilitate the movement of the mitochondria 
in areas of high metabolic demands and increased energy consumption [57]. It is 
noticed that disruption of axonal transport of mitochondria occurs as an early phe-
nomenon in cases of neuroinflammation [58], including multiple sclerosis [59–61].
6. Clinical expression of mitochondrial dysfunction
A considerable number of syndromes have been described with marked neuro-
logical phenomena in the spectrum of mitochondrial disorders [62]. The severity of 
the clinical manifestation of mitochondrial dysfunction varies considerably, given 
that there exists a threshold in the degree of mitochondrial deficiency for the clini-
cal expression of the disease [63, 64]. Thus, the symptoms and clinical phenomena 
are continuously aggravated, in the majority of the cases of mitochondrial diseases, 
as the age of the patients advances [65]. It is reasonable to accept that organs with 
high energy demand would be more seriously affected by the mitochondrial dys-
function than others with low level of energy necessity. Thus the brain, the skeletal 
muscles, and the heart have a typical involvement in adolescence and adulthood, 
though multi-system manifestation is not also an uncommon phenomenon, espe-
cially in childhood.
Many clinical syndromes have been described that are associated with mito-
chondrial dysfunction including encephalomyopathy, stroke-like episodes, 
myoclonic epilepsy, neuro-gastrointestinal phenomena, cranial or peripheral neu-
ropathy, ataxia, retinitis pigmentosa, chronic progressive external ophthalmoplegia 
which are associated frequently with lactic acidosis, mental retardation, or progres-
sive mental decline [66].
In addition, oxidative stress, due to mitochondrial dysfunction, plays a principal 
role, as causative factor, in the neurodegeneration [67] and in Alzheimer’s disease 
particularly [68, 69], and it is considered as been among the potential risk factors 
for the neurometabolic and neoplastic diseases, as well as obesity [70].
Molecular genetic testing on one hand and muscle biopsy on the other hand for 
the histochemical investigation in light microscopy and the ultrastructural study 
in electron microscopy of the muscle tissue are essential diagnostic procedures for 
approaching the diagnosis of mitochondrial disorders [71]. In addition, biochemi-
cal testing in blood, urine, and spinal fluid associated with neuroimaging [72] 
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would be useful diagnostic procedures in following in time the progression of 
 mitochondrial diseases [71].
7. The final escape
A final escape from the labyrinth of mitochondrial-related neurological dis-
orders is extremely difficult and less pragmatic under the present circumstances. 
Prospectively, an efficient treatment could be based on a stable modulation of 
mtDNA heteroplasmy [73], whereas gene therapy, gene transfer, and tRNA-targeted 
therapeutic attempts [74] as well as stem cell therapy for nuclear DNA mutations 
[75, 76] are very promising therapeutic endeavors with substantial medical and 
scientific value [77, 78].
In addition, an efficient and easy to apply treatment of mitochondrial dysfunc-
tion would open new bright horizons in the therapy of the inflammatory and 
neurodegenerative disorders [79], being beneficial in the amelioration of the quality 
of life of a substantial number of seriously suffering human beings.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Abstract
Adrenal gland is an endocrine organ comprising of an outer cortex and inner 
medulla. These secrete various hormones that have a vital role in maintaining the 
normal homeostasis of the body. Lesions of adrenal cortex are quite common to 
encounter and most of these are related to the hormones secreted by three layers of 
adrenal cortex: the zona glomerulosa, the zona fasciculata, and the zona reticularis. 
Also it is very infrequent to encounter metastatic lesions in the adrenal glands too. 
So it is very important as a part of a clinician as well as a pathologist to know the 
pattern in which these hormones are secreted along with their physiological roles. 
Thus this chapter includes the disease that are related to excess as well as deficien-
cies of the hormones secreted by adrenal cortex. The chapter also includes various 
genetic syndromes that are associated with the disorders associated with hormones 
of adrenal cortex. The last part of the chapter includes a brief description of 
various benign as well as malignant lesions, the pathological as well as the etiologi-
cal aspects and the hormonal abnormalities associated. This chapter thus mainly 
focuses on the pathology associated with the adrenal cortex and hormones secreted 
by the various layers of adrenal cortex.
Keywords: adrenal cortex, hormones, Cushing syndrome
1. Introduction
Adrenal gland consists of an outer cortex and inner medulla; the cortex is 
further subdivided into three distinct zones: the zona glomerulosa, the zona fas-
ciculata, and the zona reticularis. Mineralocorticoids (aldosterone) secreted from 
the zona glomerulosa are essential for fluid and electrolyte balance and the renin-
angiotensin-aldosterone system. The fasciculata secretes glucocorticoids (mainly 
cortisol). The zona reticularis produces steroid sex hormones called androgens. 
These hormones play an important role in maintaining the normal homeostasis of 
the body [1–3]. However, it is quite common to encounter disorders related to the 
hormones of these three layers. These disorders could be possibly due to adrenal 
cortical masses secondary to cortical hyperplasia. It is very infrequent to encounter 
metastatic lesions in the adrenal glands.
This chapter mainly focuses on the pathology related to adrenal cortex which 
includes various forms of adrenocortical hyperplasia and benign and malignant neo-
plasms of the adrenal gland which lead to various hormonal imbalances encountered 
in clinical practice. Hormonal deficiency is due to inherited glandular or enzymatic 
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disorder, destruction of pituitary gland by autoimmune disorders, infection, infarc-
tion, or others [4, 5]. The major disorders of the adrenal cortex are characterized by 
excessive or deficient secretion of each type of adrenocortical hormone.
2. Functional manifestations
The lesions of the adrenal cortex could be functional as well as nonfunctional, 
which means that patients with these lesions may exhibit clinical symptoms that 
are due to hypersecretion of hormones released. Usually cortical hyperplasia 
and adenomas are nonfunctioning. The functional syndromes associated with 
pathology of adrenal cortex are hypercortisolism (Cushing’s syndrome), adrenal 
insufficiency (Addison’s disease), hyperaldosteronism, and androgen excess (adre-
nogenital syndrome) [4–9].
3. Adrenal hyperplasia
Adrenal hyperplasia is characterized as a smooth, diffuse, bilateral enlarge-
ment of the adrenal glands, wherein the glands retain their adreniform shape. 
Hyperplasia can be either macronodular or micronodular. They are commonly 
unilateral; however bilateral cases are also observed [7, 8]. Broadly adrenal cortical 
hyperplasia can be grouped into three main categories: ACTH-dependent (adreno-
corticotropic hormone), ACTH-independent, and congenital adrenal hyperplasia 
(CAH). Cushing’s syndrome is one of the common functional manifestations of 
adrenal gland hyperplasia and therefore is discussed first [8, 10, 11].
3.1 Cushing’s syndrome
3.1.1 Definition
It is a syndrome which encompasses various clinical features due to chronic 
excess of glucocorticoids. The incidence is nearly 1–2 per 100,000 population 
per year. Harvey Cushing was the first to observe pituitary adenomas associ-
ated with hypercortisolism in 1932 [10–13]. Cushing’s syndrome, caused by 
prolonged exposure of tissues to high levels of cortisol, presents as constella-
tion of symptoms including central obesity, muscle fatigue/atrophy, hirsutism, 
infertility, osteoporosis, moon facies, dorsocervical and supraclavicular fat pads, 
and wide purple striae [8, 10, 12]. The syndrome may be ACTH-dependent or 
ACTH-independent. A fair number of cases attributed to iatrogenic causes are 
also identified. Most of the cases of Cushing’s syndrome are due to ACTH hyper-
secretion from the anterior pituitary and are associated with pituitary cortical 
adenoma. Majority of the cases, about 80–90%, show diffuse hyperplasia of the 
adrenal cortex [9, 10]. Nearly 15% of cases do present with ectopic ACTH secre-
tion associated with small cell lung carcinoma or bronchial carcinoid. Thymic 
carcinoids, pancreatic islet cell tumor, pheochromocytomas, and medullary 
carcinoma of thyroid form minor group of tumors associated with ectopic ACTH 
secretion [12]. In a study by Ejaz et al., lung tumors constituted 44.4% of all cases 
of neoplasm-related ectopic ACTH secretion causing Cushing’s syndrome [14]. 
Clinically patients with Cushing’s syndrome present with diastolic hypertension, 
hypokalemia, and edema. Hypogonadism and amenorrhea can also be seen in 
these patients which are attributed to suppression of gonadotropin secretion 
secondary to excess glucocorticoid secretion [10–14].
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3.1.2 Cushing disease
Cushing disease, resulting from a pituitary corticotropic adenoma, and rarely 
carcinoma, makes up to 80–85% of endogenous Cushing’s syndrome cases [8, 10, 15].
3.1.3 Investigating a case of Cushing’s syndrome
A two-stage test is usually recommended in a patient to rule out Cushing’s 
syndrome [8, 10, 15–17]:
1. The first group of tests are to screen for the evidence of hypercortisolism. These 
comprise urine cortisol excretion and low-dose dexamethasone suppression test.
2. The second group of tests comprise of the diagnostic tests which help to 
determine the cause of excessive production of cortisol. These are:
a. Plasma ACTH measurement: Low plasma ACTH level suggests an adrenal 
cause of the disease; however normal/high [ACTH] level suggests ectopic 
ACTH secretion or hypersecretion of ACTH from pituitary (Cushing’s 
disease).
b. High-dose dexamethasone suppression test: In this test the patient is 
administered with 2 mg of dexamethasone, 6 hourly for 48 h, following 
which plasma cortisol levels are measured. In the case of ectopic ACTH 
secretion or adrenal limited hypercortisolism, there is a failure of suppres-
sion of cortisol secretion. Also it is important to remember that cortisol is 
not suppressed with either low- or high-dose dexamethasone suppression 
in adrenal hyperplasia associated with ectopic ACTH production [18].
3.1.3.1 The 24-h urinary-free cortisol test
This investigation is used primarily for the diagnosis of hypercortisolism due 
to Cushing’s syndrome, and reference ranges for this test with respect to age are 
1.4–20 μg/24 h (3–8 years), 2.6–37 μg/24 h (9–12 years), 4–56 μg/24 h (13–17 years), 
and 3.5–45 μg/24 h in individuals ≥18 years of age. A 24-h urine sample with boric 
acid (10 g) as preservative is advisable for performing this analysis [10, 17–19].
3.1.4 ACTH-independent Cushing’s syndrome
Nearly 15–20% of Cushing’s syndrome are associated with ACTH-independent 
hypercortisolism and are secondary to a functioning adenoma or carcinoma. 
Diagnosis of ACTH-independent Cushing’s syndrome includes clinical features of 
hypercortisolism, absence of serum cortisol diurnal rhythm, elevated late-night 
cortisol levels, and incomplete suppression of cortisol production with low-dose 
dexamethasone suppression test [10, 17–20].
3.1.5  Pathological findings 
Adrenal glands from patients with Cushing’s syndrome/hyperplasia appear 
variably enlarged in size and weigh approximately 6–12 g. The cortical width is 
widened as compared to the reticulosa. The zona fasciculata usually shows nodular 
hyperplasia. Nearly 10–20% of the patients reveal bilateral nodular hyperplasia, and 
up to 30% of patients may have normal adrenal morphology [2, 20, 21].
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3.2 Primary pigmented nodular adrenocortical disease (PPNAD)
Primary pigmented nodular adrenocortical disease is a rare cause of childhood 
Cushing’s disease having female preponderance, whereas Cushing’s disease is 
common in prepubertal males [20–22]. It is the main endocrine manifestation of 
Carney complex (a multiple neoplasia syndrome caused by mutation in PRKAR1A 
gene) [23]. This is an autosomal dominant syndrome and is characterized by 
cutaneous lentigines, myxoma, schwannomas, and endocrinopathy [11, 23]. It was 
first described by Aidan Carney and co-workers in 1985. Almost 25–30% of patients 
with Carney complex have ACTH-independent Cushing’s syndrome. Cutaneous 
pigmentation is the commonest manifestation of the disease [24]. Lentigines are 
seen in most patients, and this characteristic manifestation can be used to make 
the definitive diagnosis. The name is derived from the macroscopic appearance of 
the adrenals that show characteristic small pigmented micronodules in the adrenal 
cortex. The disease typically involves bilateral adrenal glands. Grossly the adrenal 
glands may have variable size. The most characteristic finding is the presence of 
multiple brown-black pigmented cortical nodules that measure 1 mm to 3 cm in 
diameter. The adjacent cortical tissue invariable shows atrophy. These pigmented 
nodules may extend into corticomedullary junction or peri-adrenal fat [9, 11, 24].
On microscopy these tumors appear as sharply circumscribed, unencapsulated 
tumors composed of large eosinophilic lipid-poor cells similar to the zona reticularis 
arranged predominantly in trabecular growth pattern. However the nucleus appears 
enlarged, with a variable degree of pleomorphism and prominent nucleoli. There is 
prominent lipofuscin deposit. Lipid-rich fasciculata-like cells are also seen invari-
ably. The tumor may have focal areas of necrosis, mitotic activity, myelolipomatous 
change, and lymphocytic infiltrates [9, 11, 24].
3.3 ACTH-independent macronodular adrenal hyperplasia (AIMAH)
(Synonyms: ACTH-independent massive bilateral adrenal disease, massive 
macronodular hyperplasia, giant macronodular adrenal hyperplasia, macronodular 
adrenal hyperplasia, macronodular hyperplasia).
AIMAH is a disorder characterized by bilateral adrenocortical nodules, associ-
ated with ACTH-independent hypercortisolism, without any clinical features of 
pigmented nodular adrenocortical disease and histological features consistent with 
atrophic internodular cortex [25]. It is a rare cause of ACTH-independent Cushing’s 
syndrome with slightly male preponderance. The patients present usually at later 
age (average: 48 years) [24–26]. In few patients with AIMAH, ectopic expression 
and/or increased sensitivity to gastric inhibitory peptide, vasopressin receptors, 
and beta-adrenergic receptors is also seen [25].
Grossly these lesions are characterized by nodules in the adrenal cortex, ranging 
from 1 to 4.2 cm. The adrenal gland weighs approximately 16.7–218 g. The adrenal gland 
may have a large mass of cortical tissue and multiple bilateral nodules measuring up to 
5 cm. Combined adrenal gland weight of more than 300 g has also been noted (normal 
range: 8–12 g). Histology demonstrates large, yellow macronodules comprising of small 
cells with eosinophilic cytoplasm. Bilateral adrenalectomy and well-controlled gluco-
corticoid replacement is the most accepted treatment modality [2, 3, 9, 25, 26].
3.4 Congenital adrenal hyperplasia
CAH is an autosomal recessive disorder characterized by impaired steroido-
genesis finally leading to mineralocorticoid and cortisol deficiency secondary to 
reduced activity of enzymes required for cortisol biosynthesis in the adrenal cortex. 
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These patients usually present during the perinatal period with ambiguous genitalia 
in females and salt wasting in males. The milder forms of disease may present later 
with virilization at puberty or even as irregular menses. Most of the cases (nearly 
95%) are attributed to deficiency of the 21-hydroxylase enzyme [27, 28].
Abnormal growth and development, adverse effects on bone and the cardiovas-
cular system, and infertility are few long-term effects seen in these patients. These 
patients are usually managed by reducing glucocorticoid exposure and improving 
excess hormone control [29, 30].
Congenital adrenal hyperplasia can be of four forms [8–10, 27–30]:
1. Congenital adrenal hyperplasia: classical 21-hydroxylase deficiency
2. Simple virilizing congenital adrenal hyperplasia
3. Non-classic or late onset form of congenital adrenal hyperplasia
4. Congenital adrenal hyperplasia with steroidogenic acute regulatory (StAR) 
mutation
3.4.1 Congenital adrenal hyperplasia: Classical 21-hydroxylase deficiency
This form is the most common form of CAH, occurring due to 21-hydroxylase  
(21-OH) deficiency, accounting for almost 90% of the cases. It occurs with the 





Adrenocortical lesions are seen in nearly 36–41% of individuals with MEN type 
I syndrome, the commonest being bilateral nonfunctioning adrenal cortical 
hyperplasia or adenoma; adrenocortical carcinoma is exceedingly rare. The 
pathogenesis of these lesions is proposed to be due to influence of locally secreted 
insulin and insulin-like growth factors and not due to menin gene mutations
Carney complex This syndrome encompasses multiple endocrine hyperplasia, with tumors of two 
or more endocrine glands, including primary pigmented adrenocortical disease 
(PPNAD), GH- and prolactin-producing pituitary adenomas, testicular neoplasms, 
thyroid adenoma or carcinoma, and ovarian cysts. This autosomal dominant 
syndrome is mapped to two genetic loci, one present on chromosome 2p16 and 




This syndrome is characterized by gigantism, ear lobe pits and/or creases, 
macroglossia, and defects in the abdominal wall and is associated with chromosomal 
aberration of 11p15.5. These individuals are at higher risk of developing benign 
or malignant tumors of multiple organs, commonest being Wilms’ tumor, 
rhabdomyosarcoma, hepatoblastoma, and adrenal carcinoma
Li-Fraumeni 
syndrome
Rare, autosomal, dominant familial syndrome with high incidence of multiple 
malignancies at an early age, including breast cancer, leukemias, soft tissue 
sarcomas, gliomas, laryngeal carcinoma, lung cancer, and adrenocortical carcinoma. 
The pathogenesis of this syndrome is attributed to germ-line point mutations in 
the p53 tumor suppressor gene (chromosome 17p13) in pediatric age group with 




This disease is an autosomal dominant disorder, characterized by the presence of 
multiple adenomatous polyps of the colon and rectum. The gene [adenomatous 
polyposis coli gene] is located at 5q21. These patients are at high risk to develop 
adrenocortical adenomas and carcinomas, the incidence being 7.4% higher than 
0.6–3.4% reported for normal population
Table 1. 
Hereditary adrenocortical tumor syndromes.
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deficiency also have defect in synthesizing aldosterone. These patients die in the neo-
natal period due to shock from salt wasting. CAH is associated with multiple tumors 
like testicular tumors arising from ectopic adrenal cortical rests, testicular and ovar-
ian Leydig cell tumor, and ovarian tumor of the adrenogenital syndrome as ovarian 
and paraovarian brown masses. Grossly the adrenal gland is marked enlarged having 
a cerebriform appearance. On cut surface the gland appears tan-brown in color. Under 
the microscope the adrenal gland reveals diffuse cortical hyperplasia. The cells are 
compactly arranged like how they are in the zona reticularis [2, 27–30].
Table 1 illustrates various syndromes associated with adrenocortical lesions [31].
4. Primary hyperaldosteronism (Conn’s syndrome)
This disease was defined first by Conn in 1955, with a prevalence of 5–13%. This 
syndrome is characterized by an inappropriate increase in production of aldoste-
rone which is relatively independent from the renin-angiotensin mechanism and is 
non-suppressible by sodium loading. This is one of the leading causes of secondary 
hypertension in hypertensive adults [32]. Patients with primary aldosteronism 
may exhibit adrenal cortical hyperplasia or adenoma in 30% of sporadic cases, and 
nearly 1% of sporadic cases may have adrenocortical carcinoma [33]. Clinically 
these patients present most commonly as normokalemic hypertension, and severe 
cases do show hypokalemia (Table 2).
S. no. Tests Procedure Interpretation
1. Postural testing • Performed after overnight 
recumbency
• IV catheter inserted at 7 AM (mea-
sure baseline aldosterone, cortisol, 
and PRA values at 8 AM)
• Ambulate the patient for 2 h
• Measure baseline aldosterone, 
cortisol, and PRA
• 30–50% of APAs respond to 
upright posture, and 20% of 
bilateral adrenal hyperplasia are 
unresponsive
• Diagnostic accuracy of 85%
2. 18-Hydroxycortico- 
sterone level
• Elevated (>100 ng/dL) in patients 
with APAs and is significantly 
lower in patients with IHA
• Diagnostic accuracy of 82%
Hybrid steroid levels (18-OHF 
and 18-oxoF) are high (3–30 times 
normal) in FH-I, normal to mildly 
elevated in FH-II (3–4 times normal, 
as in sporadic PA), and mildly to 








(GRA) as well as for 
those patients who 
do not have GRA
• 4-day dexamethasone suppression 
test (using a dosage of 0.5 mg every 
6 h)
• Measure aldosterone, renin, and 
cortisol levels—before suppression 
testing, after 2 days and then after 
4 days of testing
• Plasma cortisol suppression (i.e., 
<5 mcg/dL) is used as an index of 
the dexamethasone effect
• Patients without GRA: aldosterone 
levels typically fall by approxi-
mately 50% and return to the refer-
ence range by the end of testing
• Patients with GRA: persistent 
suppression of aldosterone levels to 
less than 4 ng/dL
• Sensitivity of 92% and a specificity 
of 100% for the diagnosis of GRA
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The aldosterone-to-renin ratio (ARR), a gold standard method to differentiate 
primary from secondary causes of hyperaldosteronism, is defined as the ratio of 
plasma aldosterone (expressed in ng/dL) to plasma renin activity (PRA, expressed 
in ng/mL/h). The cutoff value of ARR is 30 ng/dL per/mL per hour (or 750 pmol/L 
per ng/mL per hour). The principle behind this test is that as aldosterone secretion 
rises, PRA in ex vivo testing falls due to sodium retention. This negative feedback 
response should occur when the aldosterone levels are supraphysiologic for that 
individual patient, and PRA may fall well before plasma aldosterone is clearly 
increased. Primary aldosteronism is suspected if the ARR is >30 ng/dL per mL per 
hour. This method is also helpful in differentiating aldosterone-producing adenoma 
from bilateral adrenal hyperplasia [34].
4.1 Familial primary aldosteronism
Familial primary aldosteronism is mainly of three types, all of which are inher-
ited in an autosomal dominant manner [8, 10, 32, 33]:
1. Familial hyperaldosteronism type I (glucocorticoid-remediable aldosteron-
ism): accounts for less than 1% of cases. This disorder is caused by a recombi-
nation between the CYP11B2 and CYP11B1 genes.
2. Familial hyperaldosteronism type II: nearly 3–5% cases of primary aldosteron-
ism belong to this category and are attributed to 7p22. This disorder still lacks a 
specific gene.
 4.1.1 Gross features
Grossly, the adrenal gland in cases of idiopathic hyperaldosteronism is rather 
unremarkable or may exhibit slight enlargement. The enlargement could be due to the 
presence of micronodules or macronodules. Usually, adenomas are unilateral and soli-
tary. However few cases of bilateral disease have also been reported. These adenomas 
S. no. Tests Procedure Interpretation
4. 18-Oxocortisol and 
18-hydroxycortisol 
(>100 nmol/day)
• Markedly elevated level of GRA
5. Adrenal venous 
sampling
• Test to differentiate unilateral 
disease from bilateral disease in 
patients with PA
• ACTH may be infused into a 
peripheral vein (at a dosage of 
50 mcg/h, starting 30 min before 
sampling)
• Can be performed with cosyntro-
pin stimulation
• Calculate lateralization index (LI): 
Plasma aldosterone (PAC) and 
plasma cortisol concentration (PCC) 
in both adrenal veins is determined
• The ratio of the higher (dominant) 
over the lower (non-dominant) 
PAC/PCC ratio is used for the 
assessment of lateralization of 
aldosterone hypersecretion
• Cutoff values of 4 during 
cosyntropin stimulation and of 2 
for unstimulated AVS—criteria 
to document lateralization of 
aldosterone excess
Source: [9, 10, 33, 34].
Table 2. 
Investigations.
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are mostly intra-adrenal and do not show a capsule. Few cases may reveal the presence 
of a true capsule or a pseudocapsule [2, 3, 35]. The cut surface of this tumor appears 
homogenous and golden yellow and is classically described as “canary yellow” [2]. 
Focal areas of hemorrhage or cystic changes can be present in few cases [35].
4.1.2 Microscopic features
Microscopically these adenomas appear encapsulated by compressed fibrous 
rim or fibrous “pseudocapsule.” The tumor cells are most commonly arranged in 
the form of nests or in alveolar pattern. Occasionally these cells may be arranged 
in short cords and trabeculae. Few cases may show mixed histological patterns. 
The tumor is composed of four different varieties of cells which may be present in 
varying proportions. More commonly seen are clear cells, having optically clear 
cytoplasm and centrally placed nuclei similar to those of the zona fasciculata cells; 
then there may be cells resembling to the zona glomerulosa or zona reticularis 
which appear small with compact eosinophilic cytoplasm. Then we have cells that 
are designated as “hybrid” cells. These hybrid cells have cytological features resem-
bling both the zona fasciculata and glomerulosa (Figure 1). The uninvolved portion 
of adrenal cortex reveals atrophy. This atrophy is secondary to the negative feedback 
suppression effect of the hypothalamic–pituitary axis. Spironolactone bodies which 
appear as small, intracytoplasmic eosinophilic inclusions, round to oval, measuring 
2–12 mm, are often encountered in adrenal cortical adenoma in patients on spirono-
lactone treatment. These inclusions are delineated from the surrounding cytoplasm 
by a small, clear halo [2, 7, 9, 35].
5. Adrenal insufficiency
5.1. Introduction and definition
Adrenal insufficiency was first described by Thomas Addison in 1855 and was 
popularly known as Addison’s disease. This disorder can occur either due to fail-
ure of the adrenal gland or impairment of the hypothalamic–pituitary axis [36]. 
Clinically this syndrome is characterized by weakness, fatigue, anorexia, abdominal 
pain, weight loss, orthostatic hypotension, and salt craving. Characteristic hyper-
pigmentation is seen in patients with primary adrenal failure [37]. This disease has 
been reported in three forms [7, 9, 37]:
Figure 1. 
Section from a 22-year-old patient, presented with a 2 cm mass in the right adrenal gland. Histology reveals 
adenoma with clusters of cells with enlarged lipid-rich cytoplasm (hematoxylin and eosin stain, ×200).
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1. Primary disease also known as Addison’s disease, a result of destruction of 
90% or more of the adrenocortical gland or conditions that involve decreased 
production of adrenal steroids, resulting in subnormal synthesis of aldoster-
one, cortisol, and androgens.
2. Secondary and tertiary insufficiency occurs due to deficiency of secretion 
of corticotropin (ACTH) and corticotropin-releasing hormone (CRH), 
respectively.
Most of the cases (80–90%) of primary adrenal insufficiency are caused by 
autoimmune adrenalitis. Most of the cases fall under the autoimmune polyendo-
crinopathy syndrome (60%) [1, 2, 19, 32–34]. Cell-mediated immune mechanisms 
are implicated in pathogenesis. Various antibodies have been identified, antibod-
ies against steroid 21-hydroxylase (85% cases) and autoantigens like steroid 
17α-hydroxylase and cholesterol side-chain cleavage enzyme. Other associations 
include cytotoxic T-lymphocyte antigen 4, protein tyrosine-phosphatase non-
receptor type 22, and the MHC class II transactivator. Secondary adrenal insuffi-
ciency results from any process that involves the pituitary gland and interferes with 
corticotropin secretion. Tertiary adrenal insufficiency results from processes that 
involve the hypothalamus and interfere with secretion of corticotropin-releasing 
hormone, arginine vasopressin, or both. Suppression of the hypothalamic–pitu-
itary–adrenal (HPA) axis by long-term administration of high doses of glucocorti-
coids is the most common cause [9, 36, 38].
5.2 Laboratory investigations
The patients of AI usually present with hyponatremia and hyperkalemia due to 
decreased aldosterone. Hypoglycemia also occurs due to cortisol. Decreased levels of 
this hormone also lead to an increase in lymphocytes and eosinophils, as a result of 
decreased immune-modulatory action of hydrocortisone. Measurement of baseline cor-
tisol levels between 8:00 and 9:00 AM is the test used to diagnose AI. A serum cortisol 
level of value less than 5 μg/mL favors diagnosis of AI. Stimulation test with cosyntropin 
which stimulates the cortex helps in differentiating primary and secondary AI. In this 
test 250 μg of cosyntropin is administered intramuscularly or intravenously, and serum 
cortisol is measured 30 min after infusion. Serum cortisol value of ≥18 μg/dL  
indicates a normal response. A cortisol peak <18 μg/dL confirms the diagnosis of 
AI. Serum cortisol level ≥ 100 pg/mL confirms the diagnosis of Addison’s syndrome. 
Serum cortisol value of <10 pg/mL confirms diagnosis of secondary AI [35–39].
6.  Adrenocortical carcinoma
6.1  Definition and introduction
ACC is a highly aggressive and a very rare malignancy. The incidence of this 
malignancy is approximately 0.72 per million cases per year according to the study 
by Surveillance, Epidemiology, and End Results (SEER) database [39]. The median 
age of diagnosis is usually fifth to sixth decade; however the German ACC Registry 
reports a median age at diagnosis of 46 years with a predilection for the female 
gender (female to male ratio: 1.5–2.5:1) [35, 38, 39].
Adrenocortical carcinomas (ACC) are rare tumors with an estimated annual 
inci¬dence of 0.7–2 cases by year and a global prevalence of 4–12 cases per million 
with a 5-year survival rate inferior to 35% in most of the studies published.
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6.2 Pathogenesis of adrenocortical carcinoma
Various mutations have been implicated in association with ACC. Most common 
are germ-line TP53 mutations, associated with childhood ACCs. The adult popula-
tion shows a prevalence of 3–7% of similar mutation. Childhood ACC can be found 
in association with Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, 
Lynch syndrome, and multiple endocrine neoplasia type 1. Of late an association 
with familial adenomatous polyposis (FAP), neurofibromatosis type 1, Werner 
syndrome, and Carney complex has also been postulated [39, 40].
6.2.1 Molecular mechanisms
In ACCs, chromosomal gains were frequently observed in regions 4q, 4p16, 
5p15, 5q12–13, 5q32-qter, 9q34, 12q13, 12q24, and 19p, and chromosomal losses were 
observed at 1p, 2q, 11q 17p, 22p, and 22q. Microsatellite studies identified frequent 
allelic losses in regions 17p13, 11q15, and 2p16 (85%, 92%, and 90% of samples, 
respectively) [41–43].
Signaling pathways involved in adrenal malignant carcinogenesis [44–47]:
• p53 signaling pathway
• Wnt/beta-catenin signaling pathway
• Insulin growth factor II (IGF-II) locus
6.2.1.1 The TP53 alterations
Protein p53, “guardian of genome,” is located at the 17p13 locus, and alterations 
in this gene have been noticed in various cancers including adrenocortical carci-
noma, more so at the somatic level. p53 gene mediates cellular response to stress, 
and adult sporadic ACCs usually reveal loss of heterozygosity at this locus (nearly 
85%) [48]. Stress leads to inhibition of degradation of p53 by E3 ubiquitin ligase 
MDM2, leading to inhibition of cell cycle arrest in response to DNA damage as well 
as apoptosis. These tumors tend to be larger and present at more advanced stage of 
tumor progression with shorter disease-free survival. Various genetic alterations 
have been reported in patients with adrenal cortex carcinoma like loss of PTTG1 
has been reported in nearly 84%, mutation in retinoblastoma protein (pRb) in 
nearly 27% cases and mutation in RB1 gene in 7% of the cases. Inactivating muta-
tions or homozygous deletions of CDKN2A have also been reported in 11–16% 
cases. High-level amplifications of CDK4 and MDM2 were reported in 2–7% ACCs 
[49–51]. It is surprising to see that majority of the TP53 mutations occur at the 
DNA-binding domain. Some tumors also have shown abnormalities in genes that 
encode for negative regulators of TP53, like PTTG1 which encodes for securin, 
noted in 84% of ACC. It is considered as a marker of poor survival [44, 46, 49].
6.2.1.2 Wnt/beta-catenin signaling pathway
Wnt family consists of highly conserved growth factors having similar amino 
acid sequences and is responsible for various developmental and homeostatic pro-
cesses [4, 44, 46–48, 51]. A prevalence of 39 and 84% has been reported by various 
authors on immunohistochemistry for β-catenin. The Wnt receptor is composed 
of members of the frizzled family and low-density lipoprotein receptor-related 
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protein. β-Catenin accumulates in the cytoplasm and gets translocated into the 
nucleus and then binds with Wnt receptor leading to inhibition of the axin-adeno-
matous polyposis coli—glycogen synthase kinase 3β (GSK-3) complex. This blocks 
the phosphorylation of β-catenin, leading to increased accumulation of β-catenin 
in the cytoplasm which further translocates into the nucleus. Interaction between 
β-catenin with the T cell-specific transcription factor/lymphoid enhancer-binding 
factor-1 family of transcription factors occurs in the nucleus, thus regulating 
transcription of Wnt target genes. If Wnt stimulation of GSK-3 phosphorylating 
β-catenin does not occur, degradation by proteosomes occurs following ubiquity-
lation of this receptor. Wnt pathway has been implicated in patients with familial 
adenomatous polyposis and in the development of colorectal carcinomas as well as 
ACCs. Wnt/beta-catenin pathway can be activated in both benign and malignant 
tumors by CTNNB1 mutations and by ZNRF3 inactivation in adrenal cancer. ZNRF3 
is a recent gene that encodes a cell-surface transmembrane E3 ubiquitin ligase which 
acts as a negative feedback regulator of Wnt signaling. Recently, ZNRF3 was found 
to be the most frequently altered gene in study cohorts of ACC investigated by 
integrated genomics, with a prevalence of 21 and 19% in studies by Assié et al. and 
Zheng et al., respectively [50, 51].
6.2.1.3 Insulin growth factor II (IGF-II)
Nearly 85–90% of the adult adrenocortical carcinomas are attributed to IGF-II 
overexpression. This molecular abnormality is associated with DNA demethylation 
at IGF-II locus in most of cases. Various transcriptome studies have confirmed that 
IGF-II is the most upregulated gene in ACC [52, 53].
6.2.2 Biochemistry
ACC are the tumors characterized by adrenocortical hormone production in 
nearly 45–70% of patients. Hypercortisolism is the most common presentation of 
patients presenting with hormone excess leading to a plethora of symptoms like 
diabetes mellitus, hypertension, hypokalemia, muscle weakness/atrophy, and 
osteoporosis [40–43]. Excess of androgens which comprise nearly 40–60% of 
hormone-secreting ACCs can cause rapid-onset male pattern baldness, hirsutism, 
virilization, and menstrual irregularities in women. Estrogen production occurs in 
1–3% of male ACC patients, causing gynecomastia and testicular atrophy (through 
suppression of the gonadal axis). In the evaluation of adrenal tumors, regardless 
of size, androgen or estrogen production should always raise the suspicion of a 
malignant tumor [44].
6.2.3 Gross findings
ACCs are generally large tumors, measuring on average 10–13 cm. Only a minor-
ity of tumors are less than 6 cm (9–14%), with only 3% presenting as lesions less 
than 4 cm [2, 3, 6, 9, 35].
6.2.4 Microscopy findings
Microscopically these tumors have variable architectural patterns. The tumor 
cells are arranged in a trabecular, alveolar, or diffuse pattern. Occasionally mixed 
patterns are also noted. Some areas may also exhibit free-floating tumor cells form-
ing balls [2, 3, 6, 9, 35] (Figure 2A, B).
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Histologic criteria for malignancy in adrenal cortical tumors are assessed as 
follows [2, 3, 6, 9, 35, 43–45]:
1. High nuclear grade (grades III and IV according to the criteria of Fuhrman)
2. Mitotic rate > 5 per 50 HPF (10 HPF in each of the five areas that are most 
suspicious to be malignant)
3. Atypical mitotic figures (abnormal distribution of chromosomes or an exces-
sive number of mitotic spindles)
4. Eosinophilic tumor cell cytoplasm (>75% of tumor cells or <25% clear vacu-
olated cells resembling the normal fasciculata)
5. Diffuse architecture (>33% of the tumor forming patternless sheets of cells)
6. Necrosis (occurring in confluent nests of cells)
7. Venous invasion (endothelial-lined vessel with smooth muscle as a component 
of the wall)
8. Sinusoidal invasion (endothelial-lined vessel in the adrenal with little support-
ive tissue)
9. Capsular invasion (nests or cords of tumor extended into or through the 
capsule with the corresponding stromal reaction)
Weiss et al. proposed a scoring system which was further modified and is widely 
accepted to report adrenal cortex carcinomas. These criteria include [35, 43–45, 54] 
(Table 3).
6.2.5 Interpretation
Adrenal cortical adenoma: total score < 3.
Adrenal cortical carcinoma: total score ≥ 3.
Thus if the modified Weiss score is ≥ 3, then a diagnosis of adrenocortical 
carcinoma is given.
Figure 2. 
(A) Section from a 45-year-old patient, presented with a 13 cm mass in the left adrenal gland. Histology reveals 
clusters of cells having anisocytosis and enlarged nuclei with prominent nucleoli. The fair number of darkly 
stained atypical mitosis is also evident (hematoxylin and eosin stain, ×200). (B) Histology reveals clusters 
of cells having anisocytosis and enlarged nuclei with prominent nucleoli. The cells are separated by myxoid 
stroma. The fair number of darkly stained atypical mitosis is also evident (hematoxylin and eosin stain, ×400).
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However there are other features that may help in differentiating between 
adenomas and carcinoma. These are listed in Table 4 [35, 43–45].
7. Conclusion
Adrenal glands have an essential role in maintaining the normal hemostasis. 
However the three layers of adrenal cortex, the zona glomerulosa, zona fasciculata, 
and zona reticularis, secrete essential hormones that are involved in fluid and 
electrolyte balance, regulating renin-angiotensin-aldosterone system, production of 
glucocorticoids, and synthesis of sex hormones. These hormones play an important 
Criteria Score
Absent Present
Mitotic rate (≥6 mitotic figures/50 HPF) 0 1
Cytoplasm characteristics
[clear vs. compact (compact >75% of cells)]
0 1
Abnormal mitoses 0 1
Tumor necrosis 0 1
Invasion of the capsule 0 1
Overall score = 2 × mitotic rate + 2 × cytoplasm + abnormal mitoses + necrosis + capsular invasion.
Table 3. 
Weiss scoring for adrenocortical carcinoma.
Characteristics Adrenocortical adenoma Adrenocortical carcinoma
Macroscopy
Weight Usually less than 100 g More than 100 g
Hemorrhage +/− +++
Necrosis +/− +++















Differentiating features between adrenocortical adenoma and adrenocortical carcinoma.
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role in maintaining the normal homeostasis of the body. Various lesions in adrenal, 
benign as well as malignant, are known to cause disturbances in the internal milieu 
of our body. It is therefore essential to know the physiology as well as various types 
of disorders that can be encountered so as to define proper management of the 
patient. Also lesions of adrenal gland are attributed to various genetic abnormalities, 
knowledge of which can be implicated to study the pathogenesis and in applying this 
knowledge in prognosis as well as developing targeted therapy for these lesions.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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PET Imaging of Mitochondrial 
Function in the Living Brain
Hideo Tsukada
Abstract
In the last two and half decades, we have conducted research on brain functional 
imaging in nonhuman primates using animal positron emission tomography (PET) 
scanners with high spatial resolution. We recently designed and synthesized the 
novel PET probe [18F]BCPP-EF to quantitatively image mitochondria complex-I 
(MC-I) activity in the living brain. Brain MC-I activity, measured using [18F]
BCPP-EF, was significantly lower in aged monkeys than that in young animals, 
while no significant reduction was observed in SV2A activity, a synaptic-specific 
parameter that was measured using [11C]UCB-J. Some aged monkeys exhibited 
increased amyloid-β deposition in the brain, measured using [11C]PiB, which 
induced neuroinflammation. A positive correlation was noted with neuroinflamma-
tion, measured using [11C]DPA-713 and a negative correlation with MC-I activity. 
Furthermore, a monkey model of Parkinson’s disease prepared by the chronic 
administration of MPTP revealed suppressed MC-I activity not only in the nigros-
triatal dopamine pathway, measured using [11C]PE2I and [11C]6MemTyr, but also in 
cortical serotonergic neurons, measured using [11C]DASB. This review introduces 
the translational application of a novel PET probe for noninvasive MC-I imaging 
from preclinical to clinical PET measurements.
Keywords: brain, mitochondria, aging, neurodegeneration, PET
1. Introduction
The brain has the most complex system among all human organs and plays a 
central role in physiological, neurological, and metabolic regulation throughout the 
body. The brain is very metabolically active in proportion to its volume, consuming 
20% of total oxygen and 25% of total glucose, and each cell relies on mitochondria 
to produce energy as adenosine triphosphate (ATP). The brain consists of neuronal 
and glial cells, each of which uses the different metabolic pathways to produce ATP; 
astrocytes are highly glycolytic, while neurons depend on oxidative phosphoryla-
tion (OXPHOS) in the mitochondria [1]. The electron transport chain (ETC) for 
OXPHOS in mitochondria consists of five types of complexes from I to V, with 
complex-I (MC-I; NADH–ubiquinone oxidoreductase, EC 1.6.5.3) forming the first 
and rate-limiting steps of overall respiratory and OXPHOS.
Neuronal death is regarded the dominant cause of brain aging. The 
“Mitochondrial Free Radical Theory of Aging” considers mitochondria to be the 
main drivers of aging due to the generation of reactive oxygen (ROS) and nitrogen 
(RNS) species through the ETC, and the cumulated impairment of mitochondria 
by oxidative stress in mitochondrial lipids, proteins, and DNA leads to neuronal 
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death in the brain [2]. Neuronal damage related to impaired mitochondrial func-
tion is a hallmark for several neurodegenerative diseases, including Alzheimer’s 
(AD), Parkinson’s (PD), Huntington’s diseases (HD), as well as amyotrophic lateral 
sclerosis (ALS) and multiple sclerosis (MS).
The etiology of AD, the most prominent age-related neurodegenerative disease, 
is multifactorial and associated with various environmental and genetic factors that 
play a role in its pathogenesis. The deposition of amyloid-β (Aβ) in the brain has 
been suggested to enhance neurodegenerative damage. Structural disruption and 
loss of neuronal cells induced by Aβ, leading to neuronal network dysfunction and 
synaptic loss in the hippocampus and cerebral cortex, is associated with cognitive 
impairment in AD patient [3]. Although the molecular mechanisms underlying 
synaptic dysfunction induced by Aβ have not been fully elucidated, mitochondrial 
dysfunction caused by Aβ is associated with synaptic functional alterations in the 
living brain [3].
PD is the second most prominent neurodegenerative disease and is character-
ized by the progressive degradation of the nigrostriatal pathway with the selective 
loss of dopamine (DA) neurons, resulting in movement abnormalities such as 
resting tremor, rigidity, akinesia, and impaired postural reflexes. A hallmark of 
idiopathic PD is the deposition of Lewy bodies containing insoluble and aggregated 
α-synuclein in the cytoplasmic fraction of nigrostriatal neurons in the DA pathway 
[4]. The loss of MC-I catalytic activity in the ETC has been reported in tissues 
obtained from sporadic PD patients [5] with increased oxidative stress [6].
Regarding the noninvasive assessment of mitochondrial function in the living 
brain, we recently developed a novel probe, [18F]2-tert-nutyl-4-chloro-5-{6-[2-(2-
fluoroethyl)-ethoxyl-pyridin-3-3-ylmetoxy]-2H-pyrisazin-3-one ([18F]BCPP-EF), 
for positron emission tomography (PET) [7]. The effects of physiological aging, 
aging-related Aβ deposition, and chronic MPTP treatments on cortical MC-I 
function were assessed in conscious monkeys using [18F]BCPP-EF, with the aim of 
translating clinical PET research to AD and PD patients.
2. Effects of aging on MC-I and SV2A function in the living brain
Mitochondria from aged brains consume less oxygen and, thus, produce lower 
amounts of ATP [8]. Different types of neurons show differences in topologies 
with various numbers of synaptic connections. Since synaptic and non-synaptic 
mitochondria have different protein compositions and respiratory and ROS produc-
tion rates, synaptic mitochondria are more vulnerable to oxidative damage during 
the aging process than non-synaptic mitochondria [9]. In quantitative assessments 
of the effects of physiological aging on mitochondria and synaptic function in the 
living brain, the activities of MC-I and synaptic vesicle glycoprotein 2A (SV2A), 
an ideal biomarker for synaptic density, were comparatively evaluated in the living 
brains of young and aged rhesus monkeys.
2.1 Methods
Six young male (3–5 years old) and eight aged male (20–24 years old) rhesus 
monkeys (Macaca mulatta) were examined in the PET study using [18F]BCPP-EF for 
MC-I and (R)-1-((3-[11C]methyl-[11C])pyridine-4-yl)methyl)-4-(3,4,5-trifluoro-
phenyl)pyrrolidin-2-one ([11C]UCB-J) for SV2A [10]. MRI was performed on each 
monkey using a 3.0 T MR imager (Singna Excite HDxt 3.0 T, GE Healthcare) using a 
3D spoiled gradient echo (SPGR) sequence under pentobarbital anesthesia. To avoid 
anesthetic effects on brain function as well as PET probe kinetics, PET scans were 
37
PET Imaging of Mitochondrial Function in the Living Brain
DOI: http://dx.doi.org/10.5772/intechopen.86492
conducted under conscious condition using high-resolution animal PET scanners 
(SHR-7700 and 38,000, Hamamatsu Photonics) as reported previously [11–14].
[18F]BCPP-EF was prepared by the nucleophilic [18F] fluorination of the cor-
responding precursor, as reported previously [9]. Radiochemical purity was more 
than 99%, and specific radioactivity was 47.8 ± 12.7 GBq/μmol. [11C]UCB-J was 
labeled via the Suzuki cross-coupling of [11C]methyl iodide with a boronate precur-
sor, as reported previously [10]. Radiochemical purity was more than 98%, and 
specific radioactivity was 62.3 ± 25.1 GBq/μmol.
After overnight fast, a venous cannula for the PET ligand injection and an 
arterial cannula for blood sampling were inserted into both inferior limbs. The 
animal’s head was rigidly fixed to a monkey chair using an acrylic head-restraining 
device surgically attached on the skull. The monkey sitting in the chair was placed 
at a position in the PET gantry with stereotactic coordinates aligned parallel to 
the orbito-metal (OM) plane. After a transmission scan for 30 min using a [68Ge]-
[68Ga] rotation rod source, a dynamic emission scan with [18F]BCPP-EF or [11C]
UCB-J was conducted for 90 min after the PET probe injection as a bolus.
To assess the specificity of [18F]BCPP-EF binding to MC-I, which was previ-
ously examined in rats [15], rotenone, an MC-I inhibitor, at a dose of 0.1 mg/kg 
was infused into young monkeys through a vein cannula for 1 h, followed by [18F]
BCPP-EF injection.
PET data were reconstructed by the dynamic row action maximum likelihood 
algorithm (DRAMA) method using a 2.0-mm Gaussian post filter [16], with attenu-
ation correction using transmission scan data. Individual PET and MRI images were 
co-registered. Volumes of interest (VOIs) in brain regions were drawn manually 
on MRI, and the time activity curve (TAC) of each PET probe was taken for kinetic 
analyses. These imaging annalistic processes were performed using PMOD software 
(PMOD Technologies Ltd.).
In a quantitative analyses of [18F]BCPP-EF and [11C]UCB-J, arterial blood 
samples were frequently obtain after the PET probe injection, centrifuged to sepa-
rate plasma, and ethanol was added to some plasma samples, followed by centrifu-
gation. The supernatants obtained were developed with thin layer chromatography 
with a mobile phase of ethyl acetate for [18F]BCPP-EF and chloroform/metha-
nol = 9:1 for [11C]UCB-J, respectively. The ratio of the unmetabolized fraction was 
assessed using a phosphoimaging plate analyzed by a bioimaging analyzer (FLA-
7000, GE Healthcare).The arterial input function of unmetabolized [18F]BCPP-EF 
or [11C]UCB-J was calculated using data obtained by a correction of the radioactiv-
ity ratio in the unmetabolized fraction to total fraction. A kinetic analysis of [18F]
BCPP-EF or [11C]UCB-J was performed to calculate distribution volume (VT) using 
a Logan graphical analysis [17] with PMOD software (PMOD Technologies Ltd.).
2.2 Results
Brain TACs of [18F]BCPP-EF in young animals peaked at approximately 15 min 
after the injection, except in the occipital cortex, which peaked at 40 min, and 
TACs then were gradually eliminated with time under conscious condition. The 
pre-administration of rotenone resulted in a faster elimination rate of [18F]BCPP-EF 
from the brain than that in normal. In aged animals, the peak time of TACs shifted 
to slightly later after the injection and showed significant lower [18F]BCPP-EF 
uptake levels than those in young animals.
The washout of [18F]BCPP-EF-related radioactivity and its metabolites rate 
in plasma were very rapid, with only 10% of the non-metabolized parent probe 
remaining 60 min after the injection. These kinetic patterns of [18F]BCPP-EF were 
almost identical among control young, rotenone-treated young, and aged animals. 
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A metabolic analysis confirmed that its metabolites were very polar, indicating no 
uptake of metabolites into the brain through the blood–brain barrier. These results 
confirmed that this PET probe has ideal properties for the quantitative analysis of 
MC-I activity using a metabolite-corrected arterial input function.
As shown in the upper panel of Figure 1, VT -PET images of young brains indi-
cated that the binding of [18F]BCPP-EF was highest in the occipital cortex, higher in 
the striatum, intermediate in the frontal and temporal cortices and cerebellum, and 
lowest in the hippocampus. The pre-administration of rotenone at a dose of 0.1 mg/
kg/h significantly reduced the uptake of [18F]BCPP-EF into the young monkey 
brain, specifically in the frontal and temporal cortices and striatum. When aging 
effects on VT -PET images were assessed, the binding of [18F]BCPP-EF throughout 
the brain was significantly lowered in aged animals than in young animals, as 
shown in the lower panel of Figure 1.
The TAC of [11C]UCB-J in young animals exhibited slower kinetics than [18F]
BCPP-EF throughout the brain regions, peaking approximately 30 min after the 
injection, and TACs gradually decreased with time under conscious conditions. TACs 
in aged animals peaked 30 min after the injection and showed slightly lower [11C]
UCB-J uptake levels than those in young animals. The washout of [11C]UCB-J-related 
radioactivity and metabolic rates in plasma were slower than those of [18F]BCPP-EF, 
with 25% of the non-metabolized parent probe remaining 60 min after the injection. 
These kinetic patterns of [18F]BCPP-EF were not significantly different between 
young and aged animals. A metabolic analysis confirmed that its metabolites were 
very polar, suggesting no uptake of the metabolites into the brain through the blood–
brain barrier. These results confirmed that this PET probe is useful for the quantita-
tive analysis of SV2A activity using a metabolite-corrected arterial input function.
As shown in the upper panel of Figure 2, VT -PET images of the young brain 
revealed the highest binding of [11C]UCB-J in the frontal, temporal, and occipital 
Figure 1. 
Effects of aging on PET images of MC-I in living brains of conscious monkeys. PET scans were conducted for 
91 min using [18F]BCPP-EF for MC-I, and VT images of [18F]BCPP-EF were created using a Logan graphical 
plot analysis with metabolite-corrected plasma input.
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cortices, higher in the striatum, intermediate in the hippocampus, and the lowest 
in the cerebellum. Thus, the distribution pattern of [11C]UCB-J resembled to that of 
[18F]BCPP-EF throughout the brain of young animal.
However, in contrast to [18F]BCPP-EF, when the VT of [11C]UCB-J was compared 
between young and aged monkeys, no significant age-related changes in cerebral 
SV2A activity were detected except the olfactory bulb, as shown in the lower panel 
of Figure 2.
2.3 Discussion
The present results showed age-related reduction in mitochondria function 
assessed by MC-I activity using [18F]BCPP-EF, as reported previously [11], while 
no significant alterations in synaptic density were observed based on SV2A activity 
using [11C]UCB-J.
We evaluated [18F]BCPP-EF by in vitro (living brain slices), ex vivo (dissected 
tissues), and in vivo (living rat brains) assessments in comparison with the conven-
tional MC-I PET probe, [18F]BMS-747158-02 ([18F]BMS), which was developed as a 
myocardial perfusion PET imaging probe [18], and the results obtained suggested 
that [18F]BCPP-EF is a more suitable PET probe than [18F]BMS for MCI assessments 
in the living brain [7, 15]. [18F]BCPP-EF was characterized by (1) high specific bind-
ing with moderate affinity, (2) a proper logD7.4 value, (3) long metabolic stability 
with fast clearance in plasma, (4) sufficient brain uptake with a proper elimination 
rate from the brain, and (5) low dependency to cerebral blood flow changes [19]. 
As a PET probe, these properties of [18F]BCPP-EF may contribute for a noninvasive 
and quantitative analysis of MC-I in the living brain [11], thereby allowing for the 
high detectability of age-related reductions in MC-I activity in the living monkey 
brain. Although several postmortem in vitro studies previously reported that (1) 
Figure 2. 
Effects of aging on PET images of SV2A in living brains of conscious monkeys. PET scans were conducted for 
91 min using [11C]UCB-J for SV2A, and VT images of [11C]UCB-J were created using a Logan graphical plot 
analysis with metabolite-corrected plasma input.
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age-related brain MC-I impairments were associated with a decline in mitochondria 
respiration [20, 21] and (2) the activities of MC-I and -IV, but not MC-II, III, or V, 
decreased with aging in the brains of rodents [22] and humans [20, 21], this study 
was the first to successfully confirm age-related reductions in MC-I activity in the 
living brain of nonhuman primates [11].
As described above, [18F]BCPP-EF detected age-related reduction in MC-I activ-
ity; however, this PET probe was unable to discriminate the subdomain (synapse, 
dendrites, or soma) of MC-I that was exclusively damaged due to the limitation 
of the spatial resolution of PET. In attempts to answer this question, [11C]UCB-J, 
a novel PET probe for SV2A [10], was applied to the same subject groups on the 
assumption that if this MC-I reduction mainly reflected the presynaptic domain, 
the binding of [11C]UCB-J to SV2A will also show a similar age-related reduction 
pattern in the brain. However, contrary to this assumption, no significant changes 
in [11C]UCB-J binding to SV2A were observed, except the olfactory bulb, from those 
in the same young and aged animals applied in the assessment using [18F]BCPP-EF.
Several postmortem in vitro studies have suggested age-related reductions in 
spine density; however, these findings remain controversial. One study using rat 
brains revealed that the synaptic vesicle density in axospinous synapse, a major 
population of synapses, rapidly increased until 3 weeks old and then decreased to 
the adult level, followed by no changes in senescence [23]. However, another study 
on mouse brain showed that age-related deficits in sensory perception were not 
associated with synaptic loss in the somatosensory cortex but were related to altera-
tions in the size and stability of spine buttons [24], which might not be detected as 
the changes in SV2A activity.
The discrepancy in age-related effects between [11C]UCB-J and [18F]BCPP-EF sug-
gest that MC-I dysfunction detected by [18F]BCPP-EF mainly reflect neuronal damage 
in dendrite and soma domains and are not specific to presynaptic domain. Although 
difficulties are associated with assessing mitochondrial distribution in neuronal cells, 
it was demonstrated in the cultured neuron that more than 90% of mitochondria 
were confirmed to be in the dendrite shaft overlapping in soma and large-diameter 
proximal dendrites [25]. This localized distribution pattern of the mitochondria sug-
gests that even if mitochondria in the presynaptic domain are specifically impaired, 
difficulties may be associated with detecting changes in the minor subdomain using 
[18F]BCPP-EF. The present results also suggested that in the early stage of the aging 
process, at least, in nonhuman primates, neuronal damage in the synaptic domain, if 
any, may be too subtle to be detected as decreased [11C]UCB-J binding to SV2A.
3. Effects of amyloid-β deposition on MC-I function in the living brain
Patients of AD, the most prominent age-related neurodegenerative disease, are 
characterized by the deposition of fibrillary Aβ into senile plaques and hyperphos-
phorylated tau (P-tau) into neurofibrillary tangle (NFT) in the brain. Monomer Aβ 
has been implicated in normal developmental synaptic plasticity, for example, in 
the olfactory bulb under physiological conditions [26]. However, the aggregation 
of Aβ switches its physiological role into a pathologically toxic function; thus dense 
plaques damage the surrounding brain tissues [27], causing synaptic elimination 
and impaired synaptic function [28]. Although the molecular mechanisms underly-
ing neuronal damage induced by Aβ have not been fully elucidated, mitochondrial 
dysfunction may be associated with Aβ-induced synaptic dysfunction [3] and also 
with neuroinflammation [29], resulting in cognitive impairment in AD patients. In 
order to clarify the relationship between Aβ deposition, neuroinflammation, and 
mitochondrial function, [11C]PiB for Aβ [30], [11C]DPA-713 for translocator protein 
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(TSPO) [31], and [18F]BCPP-EF for MC-I were comparatively evaluated in the 
living brains of aged rhesus monkeys. Furthermore, as a gold standard parameter of 
cerebral metabolism, [18F]fluoro-2-deoxy-D-glucose ([18F]FDG) was also applied to 
compare the diagnostic and prognostic usefulness with [18F]BCPP-EF.
3.1 Methods
Twenty aged male (20–24 years old) rhesus monkeys (Macaca mulatta) were 
investigated in the PET study using [11C]PiB for Aβ, [11C]DPA-713 for TSPO, and 
[18F]BCPP-EF for MC-I under conscious conditions using a high-resolution PET 
scanner as described in 2.1.
[11C]PiB was synthesized by the N-methylation of nor-compound N-desmethyl-
PiB with [11C]methyl triflate [30]. Radiochemical purity was more than 99%, 
and specific radioactivity was 36.7 ± 10.1 GBq/μmol. [11C]DPA-713 was syn-
thesized by the N-methylation of nor-compound N-desmethyl-DPA with [11C]
methyl triflate [31]. Radiochemical purity was more than 99%, and specific 
radioactivity was 99.3 ± 32.2 GBq/μmol. [18F]BCPP-EF was radiolabeled as 
shown in 2.1. Radiochemical purity was more than 99%, and specific radioac-
tivity was 139.6 ± 37.0 GBq/μmol. [18F]FDG was produced by the nucleophilic 
[18F]fluorination of mannose triflate following the basic hydrolysis of 2-[18F]
fluoro-1.3.4.6-tetra-O-acetyl-D-glucose.
In the analysis of [11C]PiB, standard uptake value (SUV) images from 60 to 
90 min were created, VOIs were set on each SUV images, and the SUV ratios 
(SUVR) of each region (SUVreg) against SUV in the cerebellum (SUVcereb) were 
calculated [32]. In the analysis of [11C]DPA-713, SUV images from 40 to 60 min 
were created, and VOIs were set on each SUV image. Since any cerebral regions were 
not applicable as the reference region with negligible TSPO levels [33], the SUV, 
not SUVR, was assessed. A quantitative analysis of [18F]BCPP-EF was performed as 
described in 2.1. During PET scanning with [18F]FDG, continuous arterial sam-
pling was conducted, and PET images from 40 to 60 min after the injection were 
obtained to calculate the regional cerebral metabolic rate of glucose (rCMRglc) 
using an autoradiographic method. The rCMRglc ratios of each region (rCMRglc-
region) against rCMRglc in the cerebellum (rCMRglc-cere) were calculated [34].
3.2 Results
Since the cortical VT values of [18F]BCPP-EF in aged monkeys were previously 
shown to have a higher CV value of ca. 25% than those in young ones of ca. 7% 
[11], the reasons for the lager variation of MC-I activity were elucidated using PET 
imaging with [11C]PiB for Aβ deposition and [11C]DPA-713 for TSPO in 20 aged 
monkeys. Figure 3 shows the PET/MRI images of aged monkeys with the lowest (A) 
and highest (E) [11C]PiB binding, with high SUV not only being detected in cortical 
but also subcortical regions. PET results obtained with [11C]PiB were supported 
by an immunohistochemical assessment conducted after PET assessments [12]. 
The images of [11C]DPA-713 (B and F) corresponding to each monkey (A and E) 
revealed that monkeys with the lowest (A) and highest (E) [11C]PiB binding showed 
the lower (B) and higher (F) [11C]DPA-713 binding. In contrast, the images of [18F]
BCPP-EF corresponding to each monkey with the lowest (A) [11C]PiB binding 
exhibited higher [18F]BCPP-EF uptake (C), while those with the highest [11C]PiB 
binding (E) showed the lower [18F]BCPP-EF uptake (G).
As shown in Figure 4A, when the SUV values of [11C]DPA-713 were plot-
ted against the SUVR of [11C]PiB in the cortical VOIs of all animals, the results 
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obtained revealed a significant positive correlation between each parameter, indi-
cating that Aβ deposition-induced neuroinflammation in the living brains of aged 
monkeys. In contrast, the plotting of VT of [18F]BCPP-EF against SUVR of [11C]PiB 
showed a reverse correlation in the cortical VOIs of all animals, suggesting that Aβ 
deposition-induced MC-I impairments in the brains of aged monkeys (Figure 4B).
Based on Figures 3H and 4C, it is important to note that a correlation was not 
observed between glucose metabolism assessed as the SUVR of [18F]FDG and Aβ 
deposition measured as the SUVR of [11C]PiB, and this may have been due to [18F]
FDG uptake into the neuroinflammation-related activated microglial cells.
Figure 3. 
Effects of Aβ deposition on PET images of [11C]PiB (A and E), [11C]DPA-713 (B and F), [18F]BCPP-EF (C 
and G), and [18F]FDG (D and H) in living brains of conscious monkeys. PET scans were conducted in monkey 
with the lowest (A–D) and highest (E-H) Aβ deposition among 20 aged monkeys.
Figure 4. 
Correlations between the SUV of [11C]DPA-713 (A), VT of [18F]BCPP-EF (B), and rCMRglc ratio of [18F]
FDG (C) against the SUVR of [11C]PiB in cortical and hippocampal regions of living brains of aged monkeys.
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3.3 Discussion
The present results demonstrated the potential of MC-I impairment assessed 
using [18F]BCPP-EF as a useful biomarker for Aβ deposition-related neurodegen-
eration, measured using [11C]PiB, and neuroinflammation, measured using [11C]
DPA-713. In contrast, the assessment of rCMRglc using conventional [18F]FDG was 
not as sensitive for detecting the neurodegenerative damage associated with inflam-
mation in the early stage of disease onset because of [18F]FDG uptake into not only 
normal neuronal cells but also into inflammatory cells, such as activated microglia 
in the brain [15, 19, 29]. Since activated microglia dominantly facilitate glycolysis, 
not ORPHOS system through mitochondria, to produce ATP, more glucose is 
required in microglia than in normal neuron, resulting in higher [18F]FDG uptake 
than in normal cells. Thus, MC-I assessed using [18F]BCPP-EF has a potential as a 
biomarker to assess neurodegeneration more accurately without being affected by 
inflammation in the living brain.
The present PET images obtained using [11C]PiB did not reveal as prominent 
Aβ deposition in aged monkey brains as that in the brains of PD patients. Previous 
studies suggested that no species other than humans exhibited marked neuron 
loss or cognitive impairment observed as clinical grade AD in humans, and aged 
monkeys did not exhibit as high Aβ deposition as seen in AD patients [35] or [11C]
PiB binding [36] as that in AD patients. Therefore, we assumed that the aged 
monkey model exhibited a similar mild cognitive impairment (MCI)-like, not 
AD-like, state to that in humans. In the AD state after a lag period of MCI, Aβ 
deposition level reached a plateau; therefore no correlation was observed between 
[11C]PiB uptake and cognitive levels or metabolic dysfunction assessed using 
[18F]FDG [37]. In contrast, [11C]PiB may function as a quantitative and sensitive 
biomarker for Aβ-related neuronal damage in aged monkey brains resembling the 
MCI-like state in humans [38]. Furthermore, a recent study reported the primary 
role of non-deposited, non-fibrillar assembles of Aβ peptides, and, thus, they may 
become precursors for fibrillogenesis, which lead to oxidative neurotoxicity by ROS 
in the brains of very early stage of AD patients [39]. ROS-related mitochondrial 
OXPHOS failure in the brain has been implicated in neurodegenerative disorders 
[40]. Mitochondria are the main intercellular source of ROS and also the main 
target of oxidative damage, leading to the significant disruption of brain function. 
A recent study demonstrated the direct effects of Aβ on mitochondria; thus, in 
addition to extracellular deposition, Aβ was detected in cytoplasmic mitochondria 
compartments [41], leading to dysfunction with the suppressed availability of 
nucleus-encoded proteins, a decreased rate of NABH reduction, and enhanced ROS 
generation [42]. Since we previously confirmed a positive correlation between the 
VT of [18F]BCPP-EF and rCMRO2, a gold standard for brain activation [19], the Aβ 
deposition-related MC-I functional impairment observed in the present study may 
reflect diminished activity and/or the loss of neurons with neuroinflammation. The 
present study revealed a correlation between [11C]PiB binding and [18F]BCPP-EF 
uptake, demonstrating the usefulness of an assessment of MC-I for the diagnostic 
staging of MCI and early stage AD.
In the present study, TSPO activity evaluated using [11C]DPA-713, an index of 
neuroinflammation, was stronger in the aged monkey brain with higher [11C]PiB 
binding to Aβ. Furthermore, [11C]DPA-713 binding to TSPO and rCMRglc measured 
using [18F]FDG revealed a correlation (data not shown) [12]. These results suggest 
Aβ deposition-induced neuroinflammation with the activation of microglial cells.
Therefore, the detectability of MC-I impairment using [18F]BCPP-EF for neuro-
nal damage in AD appears to be superior to the assessment of glucose metabolism 
measured using conventional [18F]FDG.
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4. Effects of MPTP-induced parkinsonism on MC-I in the living brain
Patients with PD show the progressive degradation of the nigrostriatal path-
way with the selective loss of DA neurons in the substantia nigra pars compacta 
(SNc), resulting in movement disorders, which are induced after the loss of ca. 
50% of neurons in the SNc and a reduction in DA to ca. 20% of normal levels 
in the striatum [43]. A pathological hallmark of PD is Lewy bodies and Lewy 
neurites, containing intracytoplasmic insoluble and aggregated protein of 
α-synuclein [4]. The spread of these pathologies closely correlates with disease 
progression. Furthermore, an intracerebral injection of insoluble α-synuclein 
converted normal α-synuclein into an abnormal form, which then propagated 
throughout the brains of monkeys [44] and common marmosets [45]. The 
soluble, β sheet-rich oligomers of α-synuclein induced mitochondrial dysfunc-
tion by inhibiting MC-I, enhancing ROS production, and activating the mito-
chondrial permeability transition pore (PTP), leading to mitochondrial swelling 
and neuronal death [46].
Since exposure to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
induces a syndrome mimicking PD symptoms accompanied by selective DA dam-
age in the nigrostriatal pathway [47], we developed a PD model of monkeys by 
systemic and repeated MPTP administration [48, 49] and evaluated serotonin 
(5-HT) transporter (SERT) availability using [11C]-3-amino-4-(2-dimethylamino-
methylphenylsulfanyl)-benzonitrile ([11C]DASB) [50] 5-HT 1A receptor (5-HT1AR) 
binding using 4-(2′-methoxyphenyl)-1-[2′-(N-2″-pyridinyl)-p-[18F]fluoro-benza-
mido]ethylpiperazine ([18F]MPPF) [51] in parallel with DA parameters for presyn-
aptic DA synthesis (DAS) using 6-[11C]methyl-m-tyrosine ([11C]6MemTyr) [52, 
53], DA transporter (DAT) using [11C]N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-
3β-(4-methyl-phenyl) nortropane ([11C]PE2I) [54], postsynaptic DA D2R using 
[11C]Raclopride, and MC-I activity using [18F]BCPP-EF in the living brains of 
MPTP-treated monkeys [13].
4.1 Methods
Young adult male rhesus monkeys (Macaca mulatta) were used to prepare the 
PD model, as reported previously [48, 49]. MPTP at doses ranging between 0.2 and 
0.4 mg/kg in phosphate-buffered saline was injected intravenously over a 4-month 
period until stable Parkinsonian syndrome developed. MPTP-treated monkeys were 
subjected to PET scans using specific PET probes for DA, 5-HT neuronal systems, 
and MC-I under conscious condition using a high-resolution PET scanner, as 
described in 2.1. In order to avoid the potential for spontaneous recovery as well as 
direct inhibition of [18F]BCPP-EF binding to MC-I by MPTP, all PET measurements 
were started at least after 2 months after the last treatment with MPTP.
[11C]PE2I was radiolabeled by the O-[11C]methylation of its nor-compound with 
[11C]methyl triflate. Radiochemical purity was more than 98% and specific radio-
activity of 117.1 ± 42.9 GBq/μmol. [11C]6MemTyr was developed in our laboratory 
using rapid Pd(0)-mediated cross-coupling between [11C]methyl iodide and its 
boronate precursor [52, 53], showing radiochemical purity of more than 99% and 
specific radioactivity of 71.6 ± 37.4 GBq/μmol. [11C]Raclopride was radiolabeled by 
N-[11C]methylation of its nor-compound with [11C]methyl triflate. Radiochemical 
purity was more than 98% and specific radioactivity of 65.4 ± 15.8 GBq/μmol. 
[18F]BCPP-EF was radiolabeled as shown in 2.1. Radiochemical purity was more 
than 99%, and specific radioactivity was 58.9 ± 7.9 GBq/μmol. [11C]DASB was 
prepared by the N-[11C]methylation of its nor-compound with [11C]methyl triflate 
[50] with radiochemical purity of more than 99% and specific radioactivity of 
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47.6 ± 11.1 GBq/μmol. [18F]MPPF was synthesized by the nucleophilic [18F]fluorina-
tion of its nitro precursor [51] with radiochemical purity of more than 99% and 
specific radioactivity of 90.4 ± 25.6 GBq/μmol.
Quantitative analyses of [11C]PE2I, [11C]Raclopride, [11C]DASB, and [18F]
MPPF were performed with a simplified reference tissue model to calculate 
non-displaceable binding potential (BPND) [55] using PMOD software (PMOD 
Technologies Ltd., Zurich, Switzerland). As an indirect input function, TAC in the 
cerebellum was applied. A quantitative analysis of [18F]BCPP-EF was performed as 
described in 2.1. A quantitative analysis of [11C]6MemTyr to calculate the Ki value 
was performed using a multiple-time graphical analysis [56] using PMOD software 
(PMOD Technologies Ltd., Zurich, Switzerland) applying the TAC in the occipital 
cortex as an input function.
4.2 Results
The effects of chronic MPTP treatments on the DA neuronal system in the 
brain were revealed in Figure 5. PET measurements using [11C]PE2I for DAT (A), 
[11C]6MemTyr for DAS (B), and [11C]Raclopride for D2R (C) clearly imaged the 
striatum of the normal monkey brain. After the repeated treatment with MPTP, 
presynaptic DAT availability assessed using [11C]PE2I was significantly lower in the 
caudate (4.0% of normal), putamen (4.9% of normal), and SNc (18.6% of normal) 
(E) of the MPTP-treated monkey brain than in the normal monkey (A). Another 
presynaptic parameter of DAS assessed using [11C]6MemTyr was also markedly 
lower in the caudate (13.6% of normal), putamen (12.3% of normal), and SNc (41.1% 
of normal) (F) of MPTP monkey brain than in normal animal monkey brain (B). In 
contrast, no significant changes in [11C]Raclopride binding to postsynaptic D2R were 
observed in the striatum or SNc between normal (C) and MPTP-treated animals (G).
The effects of the MPTP treatments on PET images of MC-I in the brain are shown 
in Figure 5D and H. The cerebral uptake of [18F]BCPP-EF in normal monkeys showed 
homogeneous and symmetric patterns in the both hemispheres with clear separation 
of the cortical and basal ganglion regions (D). After the repeated treatment with 
MPTP, the VT of [18F]BCPP-EF exhibited significant reductions ranging between 60 
and 70% of normal levels not only in the nigrostriatal pathway with abundant DA 
neurons but also in extra-striatal non-DA regions such as the cortex (H). No signifi-
cant decreases in the VT of [18F]BCPP-EF were observed in the cerebellum.
Since the chronic treatment with MPTP, known as a DA specific toxin, unex-
pectedly induced decreases in MC-I activity in extra-striatal non-DA regions, 
another monoaminergic neuronal system of 5-HT was further evaluated. In the 
normal monkey brain, [11C]DASB binding to SERT was high in the striatal and mid-
brain regions (Figure 6A), while [18F]MPPF binding to 5-HT1AR was high in the 
cortical regions (B). The quantitative analysis of [11C]DASB revealed significantly 
lower SERT availability throughout the brain in MPTP-treated monkey, except the 
raphe nucleus (Figure 6C), than in normal monkeys (A). The reduction in [11C]
DASB availability to SERT was the greatest in the occipital cortex (19.7% of nor-
mal); intermediate in the frontal, parietal, and temporal cortices (50.0, 40.7, and 
51.6% of normal); smaller in the caudate (60.3% of normal); and the smallest in the 
putamen and SNc (66.0 and 67.7% of normal). In contrast, no significant changes 
were observed in [18F]MPPF binding to 5-HT1AR throughout the brain between 
normal (Figure 3B) and MPTP-treated monkeys (D).
In order to assess the relationship between MC-I and DA and 5-HT neuronal 
systems in MPTP-treated monkey brains, the degrees of reductions in DAT mea-
sured using [11C]PE2I, DAS measured using [11C]6MemTyr in the nigrostriatal 
pathway (caudate, putamen, and SNc), and SERT measured using [11C]DASB in 
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Figure 5. 
Effects of the MPTP treatment on PET images of DA and MC-I in living brains of conscious monkeys. PET 
scans were conducted for 91 min using [11C]PE2I for DAT (A and E) and [18F]BCPP-EF for MC-I (D and H) 
and for 60 min using [11C]6MemTyr for DAS (B and F) and [11C]Raclopride for D2R (C and D). VT images 
of [18F]BCPP-EF (D and H) were created using a Logan graphical plot analysis with metabolite-corrected 
plasma input. BPND images of [11C]PE2I (A and E) and 11C-Raclopride (C and G) and multiple-time 
graphical analysis Ki images of [11C]6MemTyr (B and F) were created using the corresponding TACs in the 
cerebellum as input functions.
Figure 6. 
Effects of the MPTP treatment on PET images of 5-HT in living brains of conscious monkeys. PET scans were 
conducted for 91 min with [11C]DASB for SERT (A and C) and [18FMPPF for 5-HT1AR (B and D). BPND 
images of [11C]DASB (A and C) and [18F]MPPF (B and D) were created using the corresponding TACs in the 
cerebellum as input functions.
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the nigrostriatal and cortical (frontal, occipital, temporal, and parietal cortices) 
regions were plotted against those in MC-I measured using [18F]BCPP-EF. Positive 
correlations were observed between the ΔBPND of [11C]PE2I and ΔVT of [18F]
BCPP-EF and between ΔKi of [11C]6MemTyr and ΔVT of [18F]BCPP-EF in the 
nigrostriatal regions. In addition to the DA system, a positive correlation was noted 
between the ΔBPND of [11C]DASB and ΔVT of [18F]BCPP-EF in the cortical regions, 
while no correlation was found between ΔBPND of [11C]DASB and ΔVT of [18F]
BCPP-EF in the nigrostriatal regions.
4.3 Discussion
The administration of MPTP causes the slow progressive loss of DA neurons 
over a period of several months, and the decrease in nigrostriatal DA levels is 
responsible for the motor symptoms of MPTP-treated animals, resembling clinical 
symptoms in PD patient. Thus, impaired ETC for OXPHOS due to a MC-I defi-
ciency may account for neuronal cell death in PD. Alternatively, the MC-I defi-
ciency in nigrostriatal DA system of PD patients may be secondary to mitochondrial 
damage due to oxidative stress. MC-I is a site of ROS production and is particularly 
vulnerable to oxidative damage [57]. The results of the present study showing a 
deficiency in presynaptic DA activity in the nigrostriatal pathway were consistent 
with the conventional theory shown above.
In contrast, the present study applying [18F]BCPP-EF, a novel PET probe for 
MC-I, demonstrated that systemic and chronic MPTP treatments induced neuronal 
damage not only in the nigrostriatal DA pathway but also in the 5-HT neuronal 
system in the cortex of the monkey brain. Recent clinical studies suggested that 
in addition to motor symptoms, which are exclusively related to the nigrostriatal 
DA system, PD is a disease associated with non-motor symptoms, such as depres-
sion and cognitive deficits, which may be related to changes in other monoamines 
(noradrenaline and serotonin) in extra-striatal regions [58]. Lewy body and neurite 
deposition, a pathological hallmark of PD, occurs within the raphe nucleus contain-
ing 5-HT neurons of the caudal brainstem [59]. Decreases in 5-HT concentrations 
have been reported in the cortical regions of the postmortem brains of PD patients 
[60]. Furthermore, PET imaging on non-depressed PD patients revealed diffuse 
reductions in SERT availability throughout the brain [61] and decreased 5-HT1AR 
binding in the brains of non-depressed and depressed PD patients [62]. The present 
results obtained in MPTP-treated monkeys were consistent with the recent clinical 
observations on 5-HT abnormalities in PD patients, which cannot be diagnosed by 
PET measurements of dopaminergic parameters only.
5. Conclusion
This chapter introduced the potential of [18F]BCPP-EF as a PET probe for the 
noninvasive and quantitative imaging of MC-I activity in the living brain. The 
detectability of MC-I impairments using [18F]BCPP-EF for neuronal damage in AD 
appears to be superior to the assessment of glucose metabolism measured using 
conventional [18F]FDG. Furthermore, impaired serotonergic neuronal function in 
cortical regions suggests a relationship with depressive syndrome in PD patients. 
PET imaging of mitochondria function using [18F]BCPP-EF will provide novel 
insights into the pathology, diagnosis, and treatment efficacy assessments of a wide 
range of neurodegenerative diseases, including AD, PD, HD, ALS, and MS.
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Mitochondrion is a multi-functional organelle, which plays important role in 
human ovarian cancers. Mitochondrial quantitative proteomics was used to detect, 
identify, and quantify proteins from mitochondrial samples prepared from ovarian 
cancer and normal control ovary tissues. A total of 5115 mitochondrial proteins 
and 1198 mitochondrial differentially expressed proteins (mtDEPs) were identified 
in human ovarian cancer compared to control tissues. Pathway network analysis 
revealed multiple pathway network changes to involve those mitochondrial proteins 
and mtDEPs. These findings provide the scientific data about the role of mitochon-
dria plays in ovarian cancer, and offer the source for discovery of mitochondrial 
biomarker for ovarian cancers.
Keywords: mitochondrial proteome, proteomics, molecular networks, biomarker, 
ovarian cancer
1. Introduction
Mitochondrion is a multi-functional organelle, which is the center of cell energy 
metabolism, cell signaling, and oxidative stress [1, 2]. Mitochondrial dysfunc-
tion is a hallmark in human ovarian cancers, and plays important roles in ovarian 
carcinogenesis, which has been looked as the cause, biomarker, and therapeutic 
target for ovarian cancers [3–5]. First, a study finds mitochondrial morphology is 
significantly changed in ovarian cancers compared to controls. Electron microscopy 
morphology study shows that mitochondria are abundant and large volume in 
ovarian cancer cells and tissues [6, 7]. Second, mitochondrial ribosomal protein-
encoding genes might be the anti-oncogenes to serve as new biomarkers and 
therapeutic targets. For example, bcl-2-interacting mitochondrial ribosomal protein 
L41 (MRPL41) is differentially expressed in carcinomas to associate with various 
epigenetic states [8]. Mitochondrial ribosomal protein S23 (MRPS23) is involved in 
cancer cell proliferation, which might serve as the therapeutic target [9]. MRPS15 
is significantly upregulated in epithelial breast cells and tissues [10]. Mitochondrial 
COX1 is expressed abnormally in multiple cancers [11–13]. Many cancer-relevant 
communication signaling pathways are linked to mitochondrial proteins. Third, 
mitochondria are the center of oxidative stress, which might be the ‘fuel’ center for 
a cancer metabolism [10]. The abnormal energy metabolism, namely the Warburg 
and reverse-Warburg effects, is the important characteristics in cancers [14]. 
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Therefore, mitochondria play important roles in tumorigenesis, proliferation, angio-
genesis, invasiveness, and metastasis of cancer cells [14, 15]. Proteins are the important 
performer in maintaining mitochondrial morphology and functions. It emphasizes 
the important scientific merits of mitochondrial proteomics in ovarian cancer research 
and clinical practice [16–22]. Mitochondrial proteins function in mutually interacted 
molecular pathway network system, which fits the real situation of ovarian cancer that 
is a multi-cause, multi-process, and multi-result disease [23–25]. It is very difficult to 
use single-parameter biomarker to predict, diagnose, and prognostic assess ovarian 
cancer, thus multi-parameter biomarkers or molecule pattern biomarker is necessary 
for ovarian cancer prediction, prevention, and treatment [26, 27]. Mitochondrial 
proteomics is an effective approach to systematically investigate the role of mito-
chondria in ovarian cancer for discovery of reliable mitochondrial protein biomark-
ers to insight into the molecular mechanism and determination of therapeutic target 
to mitochondria for ovarian cancers. Quantitative proteomic methods commonly 
include two-dimensional gel electrophoresis (2DGE) [28, 29] or two-dimensional 
difference in-gel electrophoresis (2D DIGE) [30] comparative proteomics, and gel-
free-based quantitative proteomics [14, 15], for example, isobaric tags for relative 
and absolute quantification (iTRAQ ) [31, 32], tandem mass tag (TMT) [33], or 
label-free-based quantitative proteomics [34, 35], with different advantages and 
disadvantages, respectively. Those quantitative proteomic methods can achieve a 
high-throughput and high-sensitive identification of mitochondrial proteins and 
post-translational modifications. Currently, stable isotopic labeled large-scale 
2DGE coupled with high-sensitivity liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) is able to detect, identify, and quantify up to least 500,000 
protein proteoforms in human tissue proteoforms [36, 37]. iTRAQ , TMT, or 
label-free is commonly coupled with two-dimensional LC-MS/MS (2DLC-MS/MS), 
which enables detect, identify, and quantify up to several thousands of proteins and 
PTMs, even though these gel-free methods are unable to discriminate proteoforms 
and homolog proteins [38].
Ovarian cancer is a malignant cancer with high morbidity and mortality  
[39, 40] and without clear molecular mechanisms and effectively reliable biomark-
ers for its early-stage diagnosis to improve its prognosis. This book chapter used 
iTRAQ-labeled strong cation exchange chromatography (SCX)-LC-MS/MS method 
to detect, identify, and quantify mitochondrial proteins and mitochondrial differ-
entially expressed proteins (mtDEPs) between human ovarian cancer and control 
ovary tissues. The identified mitochondrial proteins and differentially expressed 
proteins were subject to gene ontology (GO) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway network analysis for revealing pathway network altera-
tion in ovarian cancers compared to controls. Those findings provide the scientific 
data to establish mitochondrial proteomic reference map of ovarian cancer, mtDEP 
profile and the corresponding pathway network alterations to link with ovarian 
cancer pathogenesis, which is the resource for discovery of potential biomarkers 
and mitochondria-targeting drug targets for ovarian cancers.
2. Methods
2.1 Ovarian cancer tissues and preparation of mitochondria protein samples
Seven ovarian cancer tissues and eleven control ovaries with benign gynecologic 
disease were used in this study. Mitochondria were isolated and purified from 
ovarian cancer and control tissues with differential-speed centrifugation and 
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Nycodenz density gradient centrifugation. The purified mitochondria were veri-
fied with electron microscopy, and Western blot with different antibodies specific 
to different subcellular organelles, including COX4I1 (mitochondrion), flotillin-1 
(cytomembrane), GM130 (Golgi apparatus), catalase (peroxisomes), cathepsin B 
(lysosome), and lamin B (cell nucleus). The proteins were extracted from purified 
mitochondrial samples for iTRAQ-labeled quantitative proteomic analysis. The 
detailed procedure was described in our previous publications [14, 15].
2.2 iTRAQ-based quantitative proteomics analysis
The prepared mitochondrial proteins (200 μg/each sample) were treated with 
N-hydroxysuccinimide (SDT), followed by reduction, alkylation, digestion with 
trypsin, and desalination. The tryptic peptide (100 μg/each sample) was labeled 
with iTRAQ reagent, and each sample was labeled three times. The six labeled 
tryptic peptide samples were mixed, followed by peptide fractionation with 
strong cation exchange (SCX) chromatography. Each SCX-fractionated sample 
was subject to LC-MS/MS analysis on a Q Exactive mass spectrometer (Thermo 
Scientific) within a 60-min LC separation gradient to obtain MS/MS data. The 
MS/MS data were used for identity of proteins with MASCOT search engine. 
The iTRAQ reporter-ion intensities were used to quantify each protein and 
determine each mtDEPs. The detailed procedure was described in our previous 
publications [14, 15].
2.3 Bioinformatics and pathway network analysis
The identified proteins and DEPs in mitochondrial samples were subject to 
GO and KEGG pathway enrichment analysis with Cytoscape, and DAVID online 
software (https://david.ncifcrf.gov/home.jsp). Multiple Experiment Viewer 
(https://sourceforge.net/projects/mev-tm4/files/mev-tm4/) was used to make heat 
map. GO analysis included cellular component (CC), molecular function (MF), 
and biological process (BP). PANTHER (http://www.pantherdb.org/) was used to 
further enrich GO CC.
2.4 Validation of mtDEPs and molecular networks in cell models and 
mitochondrial tissues
Ovarian cancer cells TOV-21G and control cells IOSE80 were used to extract 
RNAs and proteins. Quantitative real-time PCR (qRT-PCR) was used to measure the 
mRNA expression levels of GLDC, PCK2, IDH2, CPT2 and HMGCS2 in TOV-21G 
cells compared to IOSE80 cells. Western blot was used to measure the protein expres-
sion levels of GLDC, PCK2, IDH2, CPT2 and HMGCS2 in TOV-21G cells compared 
to IOSE80 cells, and in ovarian cancer mitochondrial samples compared to control 
mitochondrial samples; and β-actin was used as internal standard for Western blot 
analysis.
2.5 Statistical analysis
For GO and KEGG enrichment analyses, p values were corrected with 
Benjamini-Hochberg (FDR) for multiple testing. For qRT-PCR and Western blot, 
the student’s t-test was used to measure between-group difference with SPSS soft-
ware 13.0, and data was presented as the mean ± SD with p < 0.05. Each experiment 
was repeated at least three times.
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3. Results and discussion
3.1 Mitochondrial proteomic profile in human ovarian cancer tissue
iTRAQ-labeling coupled with SCX-LC-MS/MS identified 5115 proteins in mito-
chondrial samples prepared from human ovarian cancer and control ovary tissues, with 
at least one peptide sequence matches (PSMs). All of identified proteins was collected 
in the supplemental Table 1 in our previous publication [15]. Those 5115 proteins 
mainly distributed within pI 3.81–12.25 and molecular weight (MW) 2.6–1158.2 kDa, 
and in multiple cell components including cell junction (0.8%), cell part (42.7%), 
extracellular matrix (0.6%), macromolecular complex (17.8%), organelle (28.2%), and 
synapse (0.3%) (Figure 1). Of them, 2565 (50.14%) were increased, and 2550 (49.86%) 
were decreased in the abundance in ovarian cancers compared to control ovaries. 
Furthermore, statistical significance analysis revealed 1198 mtDEPs in human ovarian 
cancers compared to control ovaries, including 523 (43.66%) upregulated proteins and 
675 (56.34%) downregulated proteins, with fold-change ≥1.5 or ≤−1.5, and p < 0.05. 
Those 1198 mtDEPs were collected in the supplemental Table 1 in our previous publica-
tion [14]. Those mtDEPs might be directly linked to ovarian cancer pathogenesis, and 
the potential resource for biomarkers. From a systemic molecular network angle, one 
must realize that those non-significant difference proteins might be also important in 
ovarian cancer pathogenesis because they might be the hub-molecule in a network, 
because some studies have found that some hub-molecules changed smaller than those 
boundary molecules in a molecular network in a given condition.
3.2 Pathway networks involved in mitochondrial proteins in ovarian cancer
KEGG pathway network analysis revealed 52 statistically significant pathways to 
involve mitochondrial proteins including mtDEPs in ovarian cancers compared to 
Figure 1. 
Subcellular location of 5115 proteins analyzed with PANTHER. Modified from Li et al. [15], with permission 
from Bioscientifica Ltd., copyright 2018.
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Category Term RT Count % P-value Benjamini
KEGG_PATHWAY Lysosome RT 52 1.3 3.70E−02 2.00E−01
KEGG_PATHWAY Peroxisome RT 53 1.5 8.00E−08 4.60E−06
KEGG_PATHWAY Valine, leucine 
and isoleucine 
degradation
RT 41 1.0 1.10E−07 5.50E−06
KEGG_PATHWAY Phagosome RT 77 2.1 1.20E−05 2.90E−04
KEGG_PATHWAY Citrate cycle 
(TCA cycle)
RT 19 0.8 1.80E−07 7.50E−06
KEGG_PATHWAY Oxidative 
phosphorylation
RT 94 2.0 3.40E−07 1.10E−05
KEGG_PATHWAY Glycolysis/
Gluconeogenesis
RT 33 0.8 1.60E−02 1.20E−01
KEGG_PATHWAY Fatty acid 
metabolism
RT 29 0.8 1.90E−03 2.20E−02
KEGG_PATHWAY Prion diseases RT 14 0.6 2.20E−03 2.40E−02
KEGG_PATHWAY Propanoate 
metabolism
RT 13 0.5 1.40E−03 1.60E−02
KEGG_PATHWAY Sulfur 
metabolism
RT 7 0.3 2.90E−03 3.10E−02
KEGG_PATHWAY Pyruvate 
metabolism
RT 15 0.6 5.30E−03 4.90E−02
KEGG_PATHWAY beta-Alanine 
metabolism
RT 11 0.5 3.10E−02 2.00E−01
KEGG_PATHWAY Butanoate 
metabolism
RT 10 0.4 3.30E−02 2.00E−01
KEGG_PATHWAY Tryptophan 
metabolism




RT 15 0.6 4.00E−02 2.10E−01
KEGG_PATHWAY Metabolic 
pathways
RT 524 12.6 1.30E−12 1.80E−10
KEGG_PATHWAY Carbon 
metabolism
RT 75 2.2 3.80E−12 3.70E−10
KEGG_PATHWAY 2-Oxocarboxylic 
acid metabolism
RT 9 0.4 4.30E−03 4.30E−02
KEGG_PATHWAY Glutathione 
metabolism
RT 33 0.9 4.90E−05 1.00E−03
KEGG_PATHWAY Glyoxylate and 
dicarboxylate 
metabolism
RT 15 0.6 4.20E−05 9.40E−04
KEGG_PATHWAY Porphyrin and 
chlorophyll 
metabolism
RT 14 0.6 2.10E−02 1.50E−01
KEGG_PATHWAY Ribosome RT 110 3.0 3.00E−20 8.80E−18
KEGG_PATHWAY Biosynthesis of 
antibiotics
RT 124 3.2 3.50E−11 2.60E−09
KEGG_PATHWAY Aminoacyl-tRNA 
biosynthesis
RT 24 1.0 4.30E−04 6.60E−03
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Category Term RT Count % P-value Benjamini
KEGG_PATHWAY Biosynthesis of 
amino acids




RT 10 0.4 7.80E−03 6.60E−02
KEGG_PATHWAY Proteasome RT 30 0.6 3.10E−02 2.00E−01
KEGG_PATHWAY Protein digestion 
and absorption
RT 24 1.0 2.30E−02 1.60E−01
KEGG_PATHWAY Fatty acid 
degradation





RT 86 2.4 3.20E−07 1.10E−05
KEGG_PATHWAY PPAR signaling 
pathway
RT 20 0.8 1.60E−02 1.20E−01
KEGG_PATHWAY ECM-receptor 
interaction




RT 11 0.5 1.90E−02 1.40E−01
KEGG_PATHWAY Focal adhesion RT 88 2.3 1.30E−03 1.70E−02
KEGG_PATHWAY Protein export RT 19 0.5 3.00E−03 3.10E−02
KEGG_PATHWAY Parkinson’s 
disease
RT 97 2.1 1.20E−06 3.30E−05
KEGG_PATHWAY Alzheimer’s 
disease
RT 99 2.3 3.60E−06 9.40E−05
KEGG_PATHWAY Huntington’s 
disease
RT 101 2.3 5.30E−05 1.00E−03




RT 26 1.1 1.20E−04 2.10E−03
KEGG_PATHWAY Viral myocarditis RT 21 0.9 9.10E−04 1.30E−02
KEGG_PATHWAY Cardiac muscle 
contraction
RT 25 1.0 1.30E−03 1.60E−02
KEGG_PATHWAY Staphylococcus 
aureus infection













RT 21 0.9 1.50E−02 1.10E−01
KEGG_PATHWAY Platelet 
activation
RT 58 1.3 3.40E−02 2.00E−01
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control ovaries (Table 1 and Figure 2), including phagosome, peroxisome, valine, 
leucine and isoleucine degradation, lysosome, fatty acid metabolism, citrate cycle 
(TCA cycle), oxidative phosphorylation, glycolysis/gluconeogenesis, metabolic 




RT 87 2.0 3.50E−02 2.00E−01
KEGG_PATHWAY Legionellosis RT 16 0.7 3.70E−02 2.10E−01
KEGG_PATHWAY Toxoplasmosis RT 29 1.2 4.50E−02 2.30E−01
KEGG_PATHWAY Systemic lupus 
erythematosus
RT 32 1.3 4.90E−02 2.50E−01
Modified from Li et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
Table 1. 
52 statistically significant KEGG pathways enriched from 5115 proteins in ovarian cancers.
Figure 2. 
52 statistically significant KEGG pathways enriched from 5115 proteins in ovarian cancers. Modified from Li 
et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
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pathways, carbon metabolism, glyoxylate and dicarboxylate metabolism, gluta-
thione metabolism, propanoate metabolism, sulfur metabolism, 2-oxocarboxylic 
acid metabolism, pyruvate metabolism, porphyrin and chlorophyll metabolism, 
beta-alanine metabolism, butanoate metabolism, tryptophan metabolism, arginine 
and proline metabolism, ribosome, protein processing in endoplasmic reticulum, 
biosynthesis of amino acids, aminoacyl-tRNA biosynthesis, proteasome, protein 
Accession 
number



























OPA1 51.15 44 130 1.19 3.72E−4
Q99623 Prohibitin-2 PHB2 81.61 24 220 1.26 4.44E−4
B4E3V2 cDNA 
FLJ52854, 
highly similar to 
Sequestosome-1









9.19 1 2 0.77 2.31E−3
A0A0S2Z5I6 Optineurin 
isoform 3
OPTN 7.94 2 2 0.62 1.01E−2















to Bcl-2-like 13 
protein
Bcl2-L13 13.17 2 2 0.81 3.99E−2
PSMs  =  peptide sequence matches; MW  =  molecular weight; Ratio (T/N)  =  ratio of tumors to normal controls. 
Reproduced from Li et al. [15], with permission from Bioscientifica Ltd., copyright 2018.
Table 2. 
Mitophagy adaptors and regulatory molecules involved the identified proteins in ovarian cancer biological 
system.
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digestion and absorption, ECM-receptor interaction, focal adhesion, protein 
export, signaling pathway, complement and coagulation cascades, platelet acti-
vation, PPAR pentose phosphate pathway, fatty acid degradation, vasopressin-
regulated water reabsorption, and regulation of actin cytoskeleton. Those pathway 
systems provided an overall molecular network changes in ovarian cancers, which 
might be important in ovarian cancer pathogenesis.
Among those altered pathway systems, especially interested is that mitophagy 
pathway and energy metabolism pathway were significantly changed in ovarian 
cancers compared to controls. The changed mitophagy pathway in ovarian cancer 
included phagosome, peroxisome, valine, leucine and isoleucine degradation, 
lysosome, and fatty acid metabolism pathways [15]. Mitophagy is to engulf any 
Figure 3. 
Energy metabolism pathway changed in ovarian cancer. Reproduced from Li et al. [14], with permission from 
Elsevier Inc., copyright 2018.
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material in autophagosome, and subsequently fuses with lysosomes to release 
high-energy substance such as fatty acid and amino acid. Autophagosome also com-
monly contains mitochondria, proteins, or peroxisome. Mitophagy processes are 
involved in autophagy machinery, mitophagy adaptors, and regulatory molecules 
such as Bcl2-L12, p62, OPTN, prohibitin 2, OPA1, CK, PGAM5, BNIP3L(NIX), 
and FUNDC1 (Table 2). These findings were consistent with previous studies. The 
changed energy metabolism pathway in ovarian cancers included citrate cycle (TCA 
cycle), oxidative phosphorylation, and glycolysis (Figure 3) [14], and the impor-
tant molecules were significantly changed in three energy metabolism pathways, 
including PFKM, PKM, PDHB, CS, and IDH2 (Table 3). It clearly demonstrated the 
Warburg and reverse-Warburg effects coexisted in ovarian cancers.















14 52.92 79 1.51 3.25E−03





[NAD] subunit beta 
(IDH3B)
13 41.56 43 1.75 8.69E−03
B4DJV2 Citrate synthase (CS) 13 26.93 73 1.59 4.65E−03
P50213 Isocitrate 
dehydrogenase 
[NAD] subunit alpha 
(IDH3A)




27 56.64 355 2.02 2.07E−03
A0A0A0QN99 Cytochrome b 
reductase 1 (CYB)








1 5.14 6 0.38 3.34E−04
P07919 Cytochrome b-c1 
complex subunit 6 
(QCR 6)




1 4.61 2 0.38 6.03E−04
P38919 Eukaryotic initiation 
factor 4A-III 
(EIF4AIII)
4 11.92 9 0.71 1.48E−02
Modified from Li et al. [14], with permission from Elsevier Inc., copyright 2018.
Table 3. 
Differentially expressed glycolysis/Kreb’s cycle/mitochondrial respiratory chain/RNA binding proteins in EOC.
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3.3 Potential biomarkers for ovarian cancers
Those 5115 mitochondrial proteins including 1198 mtDEPs were the resource of 
potential biomarkers for ovarian cancers. For example, mtDEPs in mitophagy path-
way and energy metabolism pathway might be effective biomarkers and therapeutic 
targets for ovarian cancer. Five mtDEPs, including GLDC, PCK2, and IDH2 in 
peroxisome pathway, CPT2 in fatty acid degradation pathway, and HMGCS2 in 
the valine, leucine and isoleucine degradation pathway were further validated by 
qRT-PCR and Western blot in ovarian cancer cells compared to normal control cells 
(Figure 4A and B), and by Western blot in the ovarian cancer tissue mitochondrial 
samples (Figure 4C). These results also confirmed the results of iTRAQ quantita-
tive proteomics.
4. Conclusions
iTRAQ-labeled SCX-LC-MS/MS quantitative proteomics was an effective method 
to detect, identify, and quantify mitochondrial proteins and mtDEPs in mitochon-
drial samples prepared from human ovarian cancer and control ovary tissues. Totally 
5115 mitochondrial proteins including 1198 mtDEPs were identified in ovarian 
Figure 4. 
Validation of potential biomarkers (GLDC, PCK2, IDH2, CPT2 and HMGCS2) in ovarian cancer cell model 
with qRT-PCR (A) and Western blot (B), and in human mitochondrial samples with Western blot (C). 
β-actin was used as internal standard. Reproduced from Li et al. [15], with permission from Bioscientifica Ltd., 
copyright 2018.
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cancers, and 52 statistically significant pathways were identified to involve those 
mtDEPs. More interested is that this study found mitophagy pathway (phagosome, 
peroxisome, valine, leucine and isoleucine degradation, lysosome, and fatty acid 
metabolism), and energy metabolism pathways (citrate cycle, oxidative phosphory-
lation, and glycolysis) were significantly changed in ovarian cancers. The important 
molecules Bcl2-L12, p62, OPTN, prohibitin 2, OPA1, CK, PGAM5, BNIP3L(NIX), 
and FUNDC1 in mitophagy pathway, and PFKM, PKM, PDHB, CS, and IDH2 in 
energy metabolism pathways were significantly changed. It clearly demonstrated 
the changed mitophagy and energy metabolism pathways played important roles in 
ovarian cancers. These findings provide the large-scale proteomic variation profiles 
and molecular network alterations for ovarian cancer, which are the important sci-
entific data to insight into the roles of mitochondrial dysfunction in ovarian cancer.
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Abstract
Mitochondria are important cellular organelles with key regulatory functions in 
energy production, oxidative balance, and calcium homeostasis. This is especially 
important in the brain, since neurons require a large number of functional mito-
chondria to supply their high energy requirement, mainly for synaptic processes. A 
decrease in the activity and quality of mitochondria in the brain, particularly in the 
hippocampus, is associated with normal aging and a large number of neurodegen-
erative diseases compromising memory function. Although synaptic and cognitive 
dysfunction is multifactorial, growing evidence demonstrates that mitochondria 
play a key role in these processes and suggests that maintaining mitochondrial 
function could prevent these age-dependent alterations. In this chapter, we will 
discuss the hippocampal mitochondrial dysfunction present in aging and how these 
defects promote age-associated synaptic damage and cognitive impairment. We 
will summarize evidence that shows how neurodegeneration can be accelerated or 
attenuated during aging by modulating mitochondrial function.
Keywords: aging, mitochondria, oxidative stress, synapses, memory
1. Introduction
Aging is an extensively studied process, identifying a growing interest in how 
and why cognitive processes are affected from a neurobiological approach [1]. 
Aging is a multifactorial biological process, characterized by deterioration of physi-
ological and cellular functions including brain function [2], where age is the main 
risk factor for the development of pathologies such as cancer, diabetes, cardiovas-
cular disorders, and neurodegenerative diseases [3]. Cognitive deterioration occurs 
during aging, where reasoning, attention, and memory, among other processes, 
decrease gradually with the age [4]. Cellular senescence and alterations to mito-
chondria and in proteolytic systems are considered hallmarks of aging [3], where 
one of the most studied is the mitochondria [5]. In fact, mitochondrial dysfunction 
has been directly associated with the aging phenotype and the majority of diseases 
that lead to cognitive damage.
Over the last decades, a great interest has arisen regarding mitochondrial struc-
ture and function due to its relation with the aging brain [5]. Mitochondria are 
organelles essential for energy production, whose size is usually 0.5–1 μm, composed 
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by two membranes, forming the intermembranous space and the mitochondrial 
matrix [6]. The outer membrane contains many copies of the transport protein porin 
(or voltage-dependent anion-selective channels (VDAC)), which allows the passage 
of molecules with a maximum weight of 5 KDalton (KDa), and the inner membrane 
forms numerous invaginations, tubular structures, called cristae [6]. Mitochondria 
are capable of remodeling their architecture through fission and fusion processes, 
allowing morphological adaptation to different situations [6]. Fission is essential for 
mitochondrial duplication and is necessary for mitophagy, allowing dysfunctional 
mitochondrial sections to be recycled. Fusion allows mitochondria to interconnect, 
allowing damaged mitochondria to maintain their function. However, fission-fusion 
processes are interrupted during aging, generating damaged mitochondria [7].
Mitochondria have a small circular genome called mtDNA, which encodes 22 
tRNAs, 2 mitochondrial rRNAs, and 13 subunits of the electron transport chain 
(ETC) [8]. mtDNA can be damaged by exposure to reactive oxygen species (ROS), 
chemical carcinogens, and ionizing radiation affecting the mitochondrial function; 
changes are also observed during aging [9]. The internal mitochondrial membrane 
contains the ETC, responsible for generating ATP. ETC is formed by five protein 
complexes; complex I (NADH dehydrogenase) receives electrons of NADH which 
pass through the ETC via oxidation-reduction reactions forming an electrochemical 
gradient that allows the formation of ATP. In addition, FADH2 donates its electrons 
to complex II (succinate dehydrogenase) performing the same action for ATP gen-
eration but at lower production levels [10]. As a secondary product, the ETC forms 
ROS, specifically by complexes I and III, but its production is controlled by antioxi-
dant enzymes [11]. Therefore, in normal conditions ROS production is moderate, 
providing certain physiological roles [11]; however, during aging ROS accumulation 
causes biological damage known as “oxidative stress” [12].
In the past, mitochondria have always been highlighted for its role in ATP 
production; however, another key function is to maintain intracellular calcium 
homeostasis [13]. The outer mitochondrial membrane is permeable to ions and 
~5 KDa metabolites because its lipid bilayer has transmembrane proteins that 
form the mitochondrial permeability transition pore (mPTP). mPTP opening and 
closing dynamics regulates the concentration of calcium [13]. However, in condi-
tions of high calcium concentrations, permanent mPTP opening generates massive 
transport of ions and small molecules <1.5 KDa through the membrane, causing 
increased ROS production, inhibition of the ETC, and mitochondrial swelling, 
which finally results in the release of pro-apoptotic factors and cell death [14].
In this chapter we will discuss the mitochondrial alterations observed in the 
brain during aging, focusing on mitochondrial functions including redox balance, 
bioenergetics, and calcium homeostasis, and its implications in the aging process. In 
addition, we will discuss the contribution of mitochondrial dysfunction to synaptic 
failure and cognitive impairment. Finally, we will summarize potential treatments 
that have been proposed to prevent or attenuate the loss of mitochondrial function 
that could be used as potential antiaging treatment.
2. Oxidative stress: the main characteristic of normal aging
Aging is a complex process that involves both intrinsic and extrinsic factors [3]. 
Several researches showed that the reduction of synaptic function during aging 
could be related to increased oxidative stress and mitochondrial dysfunction [15, 16]. 
The latter involves decreased production of energy and redox balance, activation 
of nitric oxide synthase, and an abundant generation of free radicals; meanwhile 
increased ROS production impairs neuronal function at advanced ages [17].
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Mitochondria have a pivotal role in ROS production; they are the main organelle 
producer of species such as hydrogen peroxide (H2O2), superoxide anion (O2−), and 
hydroxyl radicals (OH−) [18]. ROS comprise all molecules derived from oxygen, can 
exist independently, and contain one or more unpaired electrons in their orbitals 
[19]. Normally, mitochondria generate ROS as a result of adequate function of the 
ETC by complexes I and III in OXPHOS to produce ATP. Likewise, electrons that 
escape mitochondrial ETC can reduce oxygen to form O2− [20]. Additionally, H2O2 
is more stable than O2− and can diffuse freely through the membranes to the cytosol 
or nucleus, causing oxidative damage to many cellular compartments [21].
The mitochondrial ROS produced in normal conditions have important physi-
ological roles in maintaining cell homeostasis, participate as signaling molecules, 
and are also related to the regulation of cell survival [22]. In contrast, excessive ROS 
production promotes cellular damage [23]. For example, recent evidence suggests 
that higher mitochondrion-derived ROS result in enhanced formation of Aβ, an 
effect that is prevented with the use of antioxidants that rescue mitochondrial func-
tion in cellular and animal models of Alzheimer’s disease (AD) [24]. This suggests 
that higher ROS generation mediated by mitochondria is involved in early stages of 
age-associated diseases and during aging [25].
Cells maintain a balance between free radicals by the action of antioxidants mol-
ecules, which neutralize or remove them [22]. Cells are equipped with a variety of 
defense mechanisms to remove ROS, including antioxidant enzymes that facilitate 
antioxidant reactions and decompose ROS [26]. Among the antioxidant enzymes 
are glutathione reductase (GR), glutathione peroxidase (GPx), and catalase (CAT). 
In addition, superoxide dismutases (SODs), such as copper-zinc-superoxide 
dismutase (CuZnSOD) and manganese superoxide dismutase (MnSOD), help the 
dismutation of superoxide radicals to generate H2O2, which is further removed by 
CAT and GPx enzymes [26]. Altogether, these antioxidant defenses regulate the 
amount of ROS, preventing accumulation and oxidative stress [27].
Oxidative stress occurs when the antioxidant defense mechanisms are unable to 
neutralize free radicals in the cell. This imbalance between the production of oxida-
tive molecules and the antioxidant defense leads to an accumulation of ROS, which 
oxidize and produce damage to lipids, proteins, and DNA molecules. Similarly, ROS 
could alter many cell compartments, for example, promoting peroxidation of lipid 
membranes and inactivation of enzymes by oxidation [28].
In oxidative stress conditions, the concentration of ROS increases transiently or 
chronically, altering the cellular metabolism and its regulation [23]. Interestingly, 
these elements are implicated in the aging process, the mitochondrial free radical 
theory of aging (MFRTA) being the most accepted theory to explain the age-associ-
ated degeneration [29]. This theory exposed by Harman proposes that mitochondria 
play a central role in aging and indicates that aging is the product of accumulated 
damage caused by mitochondrial ROS in the cells and tissues of organisms [30, 31]. 
Nevertheless, this theory has also been questioned, since aging is a multifactorial 
biological process and not just the consequence of a unique factor [32]. Thus, the 
mitochondrial theory of aging is relevant since these organelles are energy sources 
for cells and coordinate important processes such as apoptosis. During aging, 
accumulation of mtDNA mutations is increased, the mitochondrial genes related 
to energy production become progressively less active, and the mitochondria are 
observed as fragmented, producing less energy [33]. The brain is particularly 
susceptible to oxidative damage being the most aerobically active organ in the body 
due to its high metabolism [34]. The brain is generally in a redox balance; however, 
the high production and accumulation of ROS accompanied by a reduction in the 
antioxidant defense system plays a key role in aging, causing damaging effects 
due to the large number of potential harmful intermediates that cause neuronal 
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dysfunction [3, 35]. In turn, increased oxygen radical-induced oxidative damage 
during aging leads to significant changes in brain mitochondrial function [29]. 
Therefore, oxidative stress is implicated in aging and a wide range of age-related 
pathologies, such as AD and Parkinson’s disease (PD), among others [3, 16, 36].
In the aged brain, a reduction in normal antioxidant defense machineries is 
observed, which increases the brain’s susceptibility to the harmful effects of oxida-
tive molecules [27, 37]. In addition to this, mitochondrial dysfunction contributes 
to ROS overproduction. It is important to emphasize that a decrease in the activity 
of oxidative enzymes accompanied by excessive production of oxidant molecules 
during aging is the main toxic mechanism that explains the neurodegeneration 
observed at an advanced age [27, 37]. Since mitochondria are the main source of 
ROS production, they are in turn more exposed to oxidative damage at a faster 
and stronger rate than other organelles and cell compartments [16]. Moreover, the 
mitochondrial antioxidant system is less active than the antioxidant systems of 
other organelles, a feature that increases with age [5]. These mitochondrial “defects” 
can greatly affect several cellular processes that contribute to the aging phenotype 
[38]. Therefore, age is an important risk factor that increases the susceptibility 
of mitochondria, making them more vulnerable to oxidative stress, resulting in 
a vicious cycle of mitochondrial dysfunction and more oxidative damage [5, 33]. 
Mitochondria should be considered as a key factor in the development of age-
related neurodegeneration, and therefore therapeutic strategies such as mitochon-
drial protectors or antioxidants that improve mitochondrial function could be used 
to prevent or delay aging.
3. Bioenergetic failure during aging
One of the main functions of mitochondria is energy production in the form of 
ATP through OXPHOS [39]. The main substrate of neurons is glucose. Through the 
glycolytic pathway, the cell generates only two ATP molecules per glucose molecule; 
however in this pathway two pyruvate molecules are produced. These molecules 
then enter the mitochondria to be oxidized in the tricarboxylic acid (TCA) cycle 
producing NADH and FADH2, which in turn enter the ETC to produce high 
amounts of ATP by OXPHOS [40]. Electrons from NADH and FADH2 are trans-
ferred through four complexes to molecular oxygen, pumping protons to the inter-
membrane space, which form a proton gradient that generates the mitochondrial 
membrane potential (Δψm). This Δψm is fundamental for adequate mitochondrial 
function, mainly for ATP synthesis by the ATPase complex [39].
Due to the importance of mitochondrial energy production, failures in 
mitochondrial bioenergetics are related to several neurological diseases such as 
amyotrophic lateral sclerosis (ALS) [41] and several age-associated neurodegenera-
tive disorders such as AD [42]. A mitochondrial failure can be caused by either 
a dysfunction in the OXPHOS complexes or by mutations in the mtDNA, which 
encodes for 13 proteins that makes the different subunits of the ETC complexes. 
Interestingly, mtDNA mutations produce a group of pathologies known as primary 
mitochondrial disorders, characterized by neurological alterations. Thus, neurode-
generation is often related to mitochondrial dysfunction as a primary or secondary 
target, mediating the pathogenic events [43]. Since the main energy source in brain 
cells is glucose oxidation, the energy obtained from the mitochondrial OXPHOS 
system is vital to fulfilling their high basal energy requirement, including mainte-
nance of the membrane potential for the propagation of electric signals, reestablish-
ment of the ion balance after the action potential (Na+/K+ ATPase activity), vesicle 
recycling, and neurotransmitter release [44].
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Therefore, a deficit in ATP production can lead to neuronal damage and finally 
cell death, producing diverse defects in brain functions as occurs during normal 
aging, considered an important risk to the development of neurodegenerative dis-
ease [45]. An example of this is the glutamate-glutamine cycle, an essential process 
for the release of glutamate from the presynaptic terminal. Glutamate uptake occurs 
in astrocytes, where it is converted to glutamine and then transferred back to glu-
tamatergic neurons. For these processes to occur, the neuron requires ATP [46], as 
well as for the accumulation of glutamate in synaptic vesicles [47]. Therefore lower 
ATP levels will result in reduced glutamate release leading to decreased excitatory 
synapsis and consequently decreased synaptic plasticity as a result of altered long-
term potentiation (LTP) and long-term depression (LTD) [48].
In addition, AD is a neurodegenerative pathology where mitochondrial defi-
ciency is observed in oxidative phosphorylation, with defective OXPHOS enzymes 
[49]. Several studies showed decreased cytochrome c oxidase activity but an 
increase in mitochondrial mRNA for complex IV, which may be a compensatory 
response for the reduced cytochrome c oxidase activity [50, 51]. Also, there is a 
decrease in NADH dehydrogenase expression and an increase in complex III mRNA 
in AD patients [51]. These defects in the OXPHOS complex impede correct ATP 
production and increase ROS production [52], which could generate damage to 
mitochondrial proteins, activate the mPTP, and mutagenize the mtDNA, leading to 
defective OXPHOS. All these mitochondrial defects can ultimately contribute to the 
characteristic synapse loss in the neocortex and hippocampus of AD patients [53], 
which correlates with cognitive impairment and memory loss. Similarly, critical 
mitochondrial dysfunction has been associated with PD. Several mutations in pro-
teins that can directly or indirectly regulate mitochondrial activity and morphology 
have been described. Examples of this are PTEN-induced kinase 1 (PINK1) which 
induced mitochondrial autophagy during stress [54] and protein deglycase (DJ-1) 
which is a multifunctional protein that reacts against anti-oxidative stress [55]. 
These two proteins are localized in the mitochondria, while parkin, another protein 
that degrades dysfunctional mitochondria, translocates to damaged mitochondria 
[54]. The first evidence that mitochondria could be related to PD was published 
by Langston et al. in 1983 where they showed that the mitochondrial complex I 
inhibitor, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can cause acute 
and irreversible parkinsonian symptoms in humans [56]. Later, other mitochondrial 
toxins such as rotenone, which induces similar symptoms to MPTP, were described, 
leading to the development of a rotenone rodent model of Parkinson’s disease [57]. 
Other studies of postmortem tissue from PD patients showed defects in complex I, 
NADH dehydrogenase in the substantia nigra [58].
Interestingly, similar bioenergetic deficits present in neurodegenerative disease 
are also seen in normal aging. In this natural process, it is well known that a large 
number of mutations accumulate in the mtDNA in different tissues, such as the 
brain and the muscle, the tissues with most accumulation of mutations, possibly 
due to the higher energetic demand [59]. For example, in a study performed with 
humans between 49 and 92 years old, they showed an increase by 25% in the muscle 
fibers that exhibit abnormalities in mitochondrial ETC in 92-year-old individu-
als compared to 49 year olds [60]. Another study showed that a mouse with a 
deficiency for mitochondrial DNA polymerase γ (POLG) had an impaired proof-
reading ability, accumulated mtDNA mutations, and presented a premature-aged 
phenotype (hair loss, graying, kyphosis, reduced survival percentage, loss of bone 
mass, etc.) at the age of 9 months [61]. These mutations can lead to mitochondrial 
dysfunction associated with a deficient respiratory chain and a decrease in ATP 
production [62]. There is evidence that the brain of aged mice (26 months old) 
contains mutations in protein-coding regions that result in significant changes 
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in the complex I subunit ND5 and complex III subunit CytB [62]. These muta-
tions may limit correct assembly of these complexes, which correlates with their 
decreased activity during aging [62]. Other studies also showed downregulation of 
several genes coding for mitochondrial proteins in heart tissue, which correlated 
with a significant decrease in the respiratory capacity of mitochondria to oxidize 
substrates [63]. In liver tissue, there is a decrease in the respiratory control ratio and 
in ADP/oxygen (an index of ATP synthesis efficiency) in senescence-accelerated 
mice (SAMP8) mitochondria [64], suggesting that at 18 months of age, there is 
insufficient ATP for normal cell metabolism, which may be due to a dysfunctional 
energy transfer mechanism.
In the brain, it is widely known that with aging there is a decrease in the electron 
transfer activity accompanied by a decrease mainly in complexes I and IV [65, 66]. 
Several studies showed that complex IV activity is decreased in substantia nigra, 
hippocampal dentate gyrus, frontal cortex, and cerebellum during aging [67, 68]. 
A study performed with aged CD1 Swiss mice showed that NADH-cytochrome c 
reductase (complexes I and III) activity is the most affected during aging, decreas-
ing by 48% in old mice (18 months), while succinate-cytochrome c reductase 
activity (complexes II and III) remain unmodified with age, indicating selective 
impairment of NADH dehydrogenase activity (complex I) during normal aging 
[69]. Likewise, cytochrome oxidase (complex IV) activity is decreased by 13% 
in old animals [69]. Additionally, there is evidence of increased expression of 
mitochondrial genes for complexes I, III, IV, and V in 18-month-old mice in the 
hippocampus, medial prefrontal cortex, and striatum [70], suggesting a compensa-
tory mechanism that could induce overproduction of ETC proteins. However, this 
increased mRNA expression is not sustained over time, since 24-month-old mice 
have decreased expression of ETC complexes [70].
Another parameter that is altered during aging is the Δψm due to increased H+ 
permeability of the inner mitochondrial membrane and a consequent failure in 
maintaining the H+ electrochemical gradient [71]. There is evidence that there is 
a decrease in the membrane potential in the cortical and striatal mitochondria of 
33-month-old rats [72]. In the same way, a study in primary cultures of glial cells 
from the brain of young (4–6 months) and old (26–29 months) mice shows a decay 
in the Δψm in astrocytes [73].
Thus, mitochondrial bioenergetic failure is a hallmark of different diseases 
including neurodegenerative disorders. Interestingly, these same patterns of 
decreased ATP production, OXPHOS failure, and depolarization of the mito-
chondrial membrane are seen during aging, a natural process of everybody’s life. 
This makes the mitochondria an important player in all neurological degeneration 
related with aging, such as synaptic failure and cognitive impairment.
4. Age-associated calcium dysregulation
Calcium (Ca+2) is an ion that participates in a wide variety of functions in the 
cells of organisms, being an intracellular regulator of many physiological processes 
[74]. Intracellular calcium signals participate in the regulation of a large number 
of processes, which include gene expression, cell cycle stages, control of muscle 
contraction, autophagy, and cell death, among other functions, being a second 
intracellular messenger [74, 75].
In the central nervous system (CNS), Ca+2 plays a very important role in the 
neuronal synapse, mainly promoting exocytosis of the synaptic vesicles in the 
presynaptic region, meanwhile in the postsynaptic site is important for regulating 
the morphology of dendritic spines and spinogenesis [76, 77]. Calcium homeostasis 
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is fundamental for correct cellular function, and the mitochondria are structures 
important for maintaining the intracellular calcium concentrations [78]. They 
participate in the local regulation of cellular Ca+2 homeostasis, since it captures 
Ca+2 from the cytosol in response to ion fluxes through channels in both the inner 
and outer plasma membranes or by release of Ca+2 from the endoplasmic reticulum 
(ER) [79]. Thus, when the cytosolic concentration of calcium increases, mitochon-
dria capture and accumulate large amounts of the ion in order to control intracel-
lular concentrations. Therefore, for appropriate neuronal functioning, adequate 
parameters of intracellular calcium concentrations must be maintained [80]. 
Interestingly, aged brain neurons are incapable of regulating intracellular calcium, 
mainly due to dysfunctional mitochondria and increased oxidative stress [78, 81].
Mitochondrial dysfunction substantially contributes to biological aging [78]. 
In aging, oxidative stress affects mitochondrial function and, therefore, its role in 
Ca+2 homeostasis [78, 82]. When calcium homeostasis is altered, it has a detrimental 
role on the aging brain and is also associated with the development of neurode-
generative diseases [83]. Several studies showed that an increase of the Ca+2 affects 
synaptic communication, neurotransmitter release, and signal transduction, all this 
generating excitotoxicity and neuronal loss [84]. In addition, these alterations could 
also contribute to memory impairment [16, 84].
In this way, since the aging is associated with a marked cognitive decline, the 
calcium imbalance hypothesis proposed by Khachaturian turns out to be well 
accepted [85, 86]. This hypothesis proposes that changes in calcium regulation 
gradually modulate normal brain aging and, at the same time, increase their vulner-
ability to neurodegenerative diseases such as AD [87]. Calcium signaling depends 
of the transient elevation of its intracellular concentration. In brain cells, reduced 
regulation of calcium homeostasis is an early event during aging, altering multiple 
signaling pathways and affecting various molecular and cellular functions [88].
Due to their high buffering capacity, mitochondria are an essential component 
for maintaining calcium homeostasis, due to their involvement in the regulation of 
intracellular calcium signaling [89]. Also, other mitochondrial characteristics that 
facilitate its role in the regulation of calcium signaling is its structural plasticity 
produced by fusion and fission processes in the mitochondrial network, as well 
as its distribution within the neuron [90]. Aging affects mitochondrial dynamics 
leading to mitochondrial fragmentation and alterations to these functions [90]. 
Studies in mitochondria isolated from the cortex of aged animals exhibited more 
ROS production and mitochondrial swelling after increased Ca+2 loading than that 
of young animals [78]. Therefore, these findings suggest that the aging increased 
the sensitivity of the mitochondria to calcium overload, generating mitochondrial 
swelling [81]. Mitochondrial swelling results in the opening of the mPTP [91], 
and in aged animals, mPTP opening occurs prematurely, indicating reduced Ca+2 
buffering during aging [78, 81].
The mPTP is a large nonselective channel located in the inner mitochondrial 
membrane and communicates the mitochondrial matrix directly with the cyto-
plasm [81]. Their opening is activated by Ca+2, phosphate, ROS, increased pH, and 
magnesium (Mg+2) [92]. Transitory opening of mPTP allows the release of excessive 
calcium ions that accumulate in the mitochondria, but prolonged opening leads to 
the movement of ions and small molecules generating depolarization of the mito-
chondrial membrane and in turn releasing pro-apoptotic factors, which results in a 
reduction of ATP and finally causes cell death [81, 91].
The structure of mPTP is not completely clear. Experimental approaches have 
distinguished several protein components such as VDAC, the adenine nucleotide 
translocase protein (ANT), and the mitochondrial matrix protein cyclophilin D 
(Cyp-D) [91]. Recent research incorporates the F1FO subunits of ATP synthase, a 
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Figure 1. 
The mitochondrial functions are impaired during aging.
key enzyme of the OXPHOS complex, which participates in ATP production and 
maintenance of the membrane potential [91]. Interestingly, deregulation of this 
enzyme associated with aging has been reported, showing decreased expression 
of OSCP and in F1FO ATP synthase activity [81, 91]. These changes have also been 
observed in imaged brains that present age-related neurodegenerative pathologies 
[81, 91]. Cyp-D is a specific mitochondrial protein and generally considered to be 
a critical component of mPTP formation [91]. Several studies indicate that Cyp-D 
is the most important component facilitating mPTP formation, thus leading to 
decreased ATP production, increasing ROS generation, and eventually causing cell 
death [81, 91], although it is not yet completely clear how Cyp-D triggers mPTP 
formation [92]. The opening of mPTP dissipates Δψm, uncoupling the mitochon-
dria and causing swelling [91]. The expression of Cyp-D increases with age and 
is related to several age-associated neurological diseases such as AD [91, 93]. For 
example, Gauba et al. have reported that Cyp-D promotes the dysfunction of ATP 
synthase F1FO, in the mitochondria of aged brains, observing a significant increase 
in the expression of this protein with age [91]. In contrast, it has been observed that 
deletion of Cyp-D improves cognitive and mitochondrial functions in both aging 
and in neurodegenerative diseases [91, 93].
81
Mitochondrial Dysfunction as a Key Event during Aging: From Synaptic Failure to Memory Loss
DOI: http://dx.doi.org/10.5772/intechopen.88445
The increased life expectancy and the high incidence of neurodegenerative 
diseases require a better understanding of the aging processes and the mechanisms 
associated with it. Thus, comprehension of the interactions between calcium 
homeostasis and calcium-dependent processes during aging can help in the design 
of more effective therapeutic strategies. Maintaining calcium homeostasis and 
controlling the opening of mPTP are important factors that can be considered as 
a potential therapeutic objective to maintain the quality of life during aging and 
prevent mitochondrial damage and progressive cognitive deterioration associated 
with age that contribute to the development of neurodegenerative diseases.
Figure 1 is a schematic representation of the main mitochondrial functions 
affected during normal aging. It shows increased oxidative stress as a result of a 
REDOX imbalance due to decreased activity of antioxidant enzymes and increased 
reactive oxygen species. It also shows the characteristic bioenergetics failure, as 
a consequence of diminished OXPHOS functioning, specifically by decreased 
activity of complexes I and IV of the ETC, which lead to reduced ATP production 
and, finally, calcium dysregulation, which leads to mitochondrial swelling due to a 
permanent opening of the mitochondrial permeability transition pore.
5. Mitochondrial dysfunction and cognitive impairment
Synaptic plasticity in the adult nervous system is a response to changes in the 
environment and synaptic activity, involving dendritic spine growth or retraction 
and synaptogenesis, which are believed to be responsible for learning and memory 
[94]. In the hippocampus, one form of synapse plasticity is LTP, which produces a 
stronger transmission for consolidation of long-term memory [95]. For this process, 
neurons need to synthesize proteins de novo at the dendritic spines where different 
neurotrophic factors play a key role [96]. An impairment in this process leads to 
neurodegeneration, as a result of the initial loss of synaptic structure and function 
and finally cell death [96].
The previously described mitochondrial dysfunction could be an important fac-
tor in synapse loss associated with cognitive decline observed during aging and in 
neurodegenerative disease [97]. Since mitochondria are present in axonal terminals 
and dendrite spines playing a critical role in calcium flux, ROS homeostasis, and 
ATP production in the synapses, this organelle is a key element for neuronal plastic-
ity [94]. In addition, mitochondrial transport to the synaptic regions is essential for 
the correct function of this neuronal network [98].
Multiple pathological conditions present cognitive impairment related with a 
mitochondrial dysfunction. For example, chronic kidney disease (CKD) patients 
with cognitive damage have increased oxidative stress and decreased antioxidant 
enzymes (SOD, CAT, GPx, and GSH levels in plasma) compared to CKD patients 
without cognitive impairment [99]. Also, patients with hypoxia, ischemia induced 
by a traumatic brain injury (TBI), and diabetes showed cognitive decline and dif-
ferent signs of mitochondrial impairment such as glutamate excitotoxicity, calcium 
overload, opening of mPTP (which dissipates the mitochondrial electrochemical 
gradient leading to cell death), and increased ROS levels [100–102]. Interestingly, 
pyramidal neurons in the cerebral cortex and hippocampus are more susceptible 
to this type of injury [103], suggesting that these cellular defects may affect mainly 
synaptic plasticity, learning, and memory.
In the context of neurodegenerative disease, mitochondrial impairment and 
oxidative stress are the target of Aβ neurotoxicity, promoting cognitive impairment 
in AD [104]. The degree of cognitive impairment in AD has been related to the 
amount of Aβ accumulated in mitochondria [105], resulting in a loss of the Δψm in 
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synaptic regions and ultimately leading to the characteristic synaptic loss observed 
in AD [106]. It has been suggest that Cyp-D can interact with Aβ contributing to 
synaptic perturbations. A Cyp-D deficiency can notably improve synaptic function 
and therefore improve learning and memory in an AD mouse model [107]. It was 
recently proposed that tau protein can regulate synaptic activity, affecting mito-
chondrial function and axonal transport [108], and post-transductionally modified 
tau can induce mitochondrial damage, leading to synaptic dysfunction [109]. In 
fact, hyper-phosphorylated tau impairs mitochondrial respiratory chain function, 
increases ROS levels, decreases the activity of detoxifying enzymes, and produces 
Δψm dissipation [108]. Thus, the accumulation of tau can lead to synaptic deficits 
and cognitive impairment [110].
Interestingly, cognitive decline is not only characteristic of disease and injury, 
since cognitive impairment is also observed during aging. During normal aging, it 
is well established that there is a reduction in the surface area and cortical thick-
ness, resulting in a volume loss in the whole brain, being the non-cortical regions, 
such as the hippocampus and striatum, more vulnerable to this age-related atrophy 
[111]. In this context, a study performed with Sprague-Dawley rats of 14, 18, 23, 
and 27 months of age showed changes in the volume of different brain parts using 
magnetic resonance imaging (MRI) [112]. In that study they showed enlargement 
of lateral ventricles and a decrease in the volume of the medial prefrontal cortex, 
hippocampus, and striatum in 27-month-old rats, which correlates with cogni-
tive deficiency. Twenty-three- and twenty-seven-month-old rats have decreased 
recognition memory and decreased spatial learning and memory [112]. Another 
common symptom of aging is cognitive fatigue (CF) characterized by an increase in 
the facility of becoming tired, lack of energy, and failure to sustain attention when 
performing cognitively demanding tasks with a high mental effort [113]. There is 
evidence of a correlation between the decreased connectivity strength of the neuro-
nal network established between the cortical and the striatum areas and a higher CF 
at an advanced age, suggesting that the cortical-striatal network plays a crucial role 
in the CF phenomenon [114].
In humans, similar cognitive decline is observed during aging, present as a 
deficit in episodic or declarative memory, spatial learning, working memory, and 
attention [115]. These processes are mainly dependent on an adequate function of 
the hippocampus. Structural and functional changes in the hippocampus are related 
to the severity and development of neurodegenerative disorders associated with 
cognitive decline. In fact, many of the cognitive deficits seen with aging can be rep-
licated in animal models with bilateral hippocampal damage [116]. The connection 
between dentate gyrus (DG) and the CA3 area of the hippocampus is responsible 
for the formation of new memories, and this is naturally decreased in the aged brain 
[117], with different biochemical modifications that affect its ability to generate and 
consolidate LTP [117]. Diverse studies have shown that during aging, the auto-
associative network of CA3 is strengthened, and the processing of new information 
coming in from the entorhinal cortex is weaker [118]. Thus, the stored information 
becomes dominant in contrast to the ability to encode new information [118]. Also, 
there is a decrease in gray matter volume, where age-related changes in the temporal 
lobe involve mainly changes in the hippocampus [4].
Also, different studies show high levels of tau in cerebrospinal fluid (CSF) 
during aging [119, 120]. For example, the characteristic hearing loss (HL) present 
in aging influences neurodegeneration by promoting tau pathology in CSF [120], 
which produces cognitive impairment via synapsis dysfunction and neuronal loss 
[110]. Other studies evidence the age-related impairment of executive functions, 
verbal and nonverbal cognitive switching (independent of gender, education, and 
IQ ), and the ability to focus attention and/or multitask [121, 122]. Studies have 
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shown that during aging, there is a reduction in inhibitory mechanisms in the CA3, 
where short-term plasticity and LTP are compromised [123]. Interestingly, mito-
chondria play a central role in LTP, enhancing mitochondrial gene expression [124], 
satisfying the ATP demand by producing changes in mitochondrial energy produc-
tion, and regulating calcium homeostasis by increasing calcium pump activity 
[125]. Also, there is evidence that mitochondrial dysfunction can lead to failure in 
connectivity of brain cortex producing cognitive impairment [126]. Thus, mito-
chondrial dysfunction during aging can be related with degeneration of synapses, 
triggering cell death.
In this mitochondrial context of aging, it is interesting that in brain regions 
highly associated with cognitive function, such as the hippocampus and cortex, 
there is a high amount of impaired mitochondria, with dysfunctional respiration, 
excessive ROS production, loss of Δψm, and decreased cytochrome c oxidase 
activity. Meanwhile mitochondria are less affected in areas of the brain that are 
less involved in cognitive abilities [105]. Therefore, mitochondrial function is a 
key component in cognition. It allows proper information processing through the 
brain network, being an important player in synaptic transmission. Mitochondrial 
dysfunction generates deficits in synapsis that trigger cognitive impairment in 
Figure 2. 
A synaptic failure leads to cognitive impairment in aging.
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neurodegenerative disease but also in natural aging. Thus, the understanding of 
these processes may be critical in these times where the aged population is increas-
ing; therefore, improving their quality of life is a priority.
Figure 2 above shows the synaptic effects of mitochondrial failure. In the 
presynaptic region, decreased mitochondrial activity diminishes ATP content, 
altering the exocytosis of synaptic vesicles. Also, increased ROS production induces 
lipid peroxidation, affecting glutamate and glucose transport. In the postsynaptic 
region, decreased mitochondrial activity disrupts calcium homeostasis, altering 
postsynaptic signaling. Besides, the increased ROS production and consequent 
lipid peroxidation impaired ion-motive ATPases. Figure 2 below schematizes that 
mitochondrial dysfunction at the CA1 of the hippocampus impaired synaptic 
transmission resulting in cognitive impairment.
6. Mitochondrial therapies as an antiaging treatment
Since mitochondrial dysfunction is a key event promoting aging, interventions 
that focus on maintaining or restoring the correct functioning of the mitochondria 
seem fundamental. For this purpose, two different experimental strategies could 
be used [127], physiological approaches or pharmacological approximations, which 
will be briefly summarized in this section.
From the physiological point of view, maintaining a lifestyle that includes 
recurrent physical exercise preserves mitochondrial function [127]. During aging 
a loss of age-associated muscle mass is directly related with decreased mitochon-
dria-dependent metabolic capacity, as well as with reduced mitochondrial bio-
genesis [128]. Biogenesis of new mitochondria is regulated by the transcriptional 
coactivator peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α), which also regulates redox balance and energetic function [129]. 
Interestingly, PGC-1α expression is decreased in aging reducing its signaling 
pathway and gene target [129], an effect that could be counteracted by exercise, 
demonstrating that exercise also increases mtDNA content in the muscle of aged 
rats [130]. In addition, exercise increases the expression of the CAT enzyme, 
reducing ROS levels [131]. Similarly, exercise promotes both fission and fusion 
events as indicated by upregulated levels of Fis1 and Mfn1 protein in the muscle 
tissue of old animals and by increased Mfn2 and Drp1 mRNA in the skeletal 
muscle of older women [132]. Finally, exercise could contribute to restoration of 
mitochondrial Ca+2 homeostasis, increasing the protein levels of mitochondrial 
Ca+2 uniporter (MCU) [132]. Thus, exercise during aging could promote the 
genesis of new mitochondria or could attenuate the mitochondrial dysfunction 
observed at an advanced age.
A second physiological approximation important for simulating mitochondrial 
function is caloric restriction, which has been demonstrated in different models 
that are able to reduce the age-related phenotype and to increase lifespan [133]. The 
beneficial effects of caloric restriction are directly associated with the bioenergetic 
defects observed in aging, activating ATP production through fatty acid metabo-
lism [134]. Mechanistically, caloric restriction increases the activity of complexes 
I, III, and IV of the ETC, as well as MnSOD, which results in increased ATP and 
reduced ROS levels [135]. Likewise, caloric restriction enhances Ca+2 mitochondrial 
buffering, decreasing Cyp-D levels [135]. Therefore, regulating caloric ingestion is 
possible for maintaining mitochondrial activity during aging.
Mitochondrial function can also be regulated pharmacologically, for example, 
through the administration of polyphenols such as resveratrol, green tea, and red 
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wine [127, 136]. Specifically, they act by promoting mitochondrial OXPHOS and 
activating cellular antioxidant mechanisms [137]. Another possibility is the use 
of antioxidant compounds such as MitoQ , an electron scavenger that prevents the 
formation of mitochondrial free radicals [138]. Similarly, α-tocopherol (MitoVitE), 
α-phenyl-tert-butylnitrone (MitoPBN), the piperidine nitroxide MitoTEMPOL, the 
antioxidant SkQ1, and elamipretide (SS-31) enter and accumulate in the mitochon-
dria preventing oxidative stress and preserving mitochondrial function [139, 140]. 
The numerous studies probing the clinical efficacy of these compounds validate 
the importance of mitochondria in aging [139]. To promote the natural antioxidant 
effect in the cell, treatment with N-acetylcysteine, vitamin, C and other physiologi-
cal antioxidant molecules have also been shown to be effective as palliative treat-
ment of senescence [141, 142].
It is also important to highlight the positive effects induced by the direct admin-
istration of fatty acids including omega-3 fatty acid α-linolenic acid, due to studies 
in vivo that have shown its capacity to extend lifespan [143]. This could be a con-
sequence of increased β-oxidation, which results in higher mitochondrial energy 
production, by increasing mitochondrial biogenesis or by reducing oxidative stress 
[144]. Finally, we will mention the effects of Metformin, a drug commonly used 
for the treatment of type 2 diabetes. Metformin has a hypoglycemic effect in the 
plasma and promotes increased insulin sensibility by a mechanism that remains 
unclear [145]. However, favorable effects have been observed, where DNA dam-
age and inflammation are prevented, impeding cellular damage by reducing ROS 
production [146].
Therefore, these approaches highlight the key role that mitochondrial function 
play during aging, where correct mitochondrial activity could extend lifespan, 
whereas metabolic alterations could compromise mitochondrial function, acceler-
ating the aging phenotype.
7.  Future directions: importance of synaptic mitochondrial dysfunction 
in aging
It is now known that the mitochondria have a fundamental role during the 
aging process. In neurons, the mitochondria are classified into two groups 
according to their localization, such as synaptic and non-synaptic mitochondria. 
Non-synaptic mitochondria are distributed throughout the cell body and in the 
neural prolongations, meanwhile synaptic mitochondria are exclusively found in 
synapses, both at the pre- and postsynaptic level [147]. Thus, it is not surprising 
that synaptic mitochondria, which have a higher energy requirement in order to 
sustain synaptic activity, present functional differences compared to non-synaptic 
mitochondria. For example, synaptic mitochondria have higher peroxide produc-
tion than non-synaptic ones [148]. During aging, it seems that these differences 
are accentuated between these two mitochondrial populations. Aged cortical 
synaptic mitochondria present decreased oxidative capacity and higher suscepti-
bility to calcium overload, in contrast to non-synaptic mitochondria that preserve 
their respiratory capacity [16]. Similarly, we observed that hippocampal synaptic 
mitochondria fail previous to non-synaptic mitochondria during aging and suffer 
premature mitochondrial swelling with age, contributing hippocampus-dependent 
memory loss (manuscript in preparation). Thus, maintaining adequate function 
of synaptic mitochondria seems to be the new challenge in order to attenuate the 
aging phenotype, reducing the synaptic and cognitive failure characteristics of 
older individuals.
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8. Conclusions
Taken together, the evidence presented in this chapter strongly suggests a 
close relationship between mitochondrial function and a wide range of processes 
associated with aging. In general, it is possible to propose an age-dependent decline 
observed in several organs such as the brain correlated with a loss of mitochondrial 
activity, generating a bioenergetic deficit and redox imbalance that promote oxida-
tive stress. This promotes additional mitochondrial fail, affecting cellular calcium 
homeostasis, critical for neurons due to its important roles in the synapses. Thus, 
synaptic defects conduce to cognitive impairment. Finally, we propose that the 
synaptic mitochondria are a critical mitochondrial pool to preserve synaptic com-
munication despite the passing of the years.
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Coenzyme Q 10 and L-Carnitine 
Disturbances in Children with 
Mitochondrial Diseases
Ekaterina A. Nikolaeva, Ilgar S. Mamedov  
and Irina V. Zolkina
Abstract
Coenzyme Q10 (CoQ10) and L-carnitine are very important biologically active 
compounds involved in energy metabolism. L-carnitine and coenzyme Q10 distur-
bances in mitochondrial diseases require the correction. Patients and methods: The 
levels of coenzyme Q10 and L-carnitine (total carnitine, free carnitine, and acyl-
carnitines) were determined in children with mitochondrial diseases (25 children 
and 16 children, respectively). High-performance liquid chromatography with UV 
detection (chromatograph Shimadzu Nexera LC-30) and chromatography-mass 
spectrometry (Agilent 6410 QQQ , USA) were used. As an additional parameter of 
possible coenzyme Q10 and carnitine insufficiency, the coenzyme Q10/cholesterol 
ratio and acylcarnitines/free carnitine ratio were calculated. Results: A significantly 
low ratio of coenzyme Q10/cholesterol in children with mitochondrial diseases 
was revealed—0.10 ± 0.01 vs. 0.19 ± 0.01 in the control group (p < 0.001). A lower 
absolute level of coenzyme Q10 and tendency toward a more pronounced decrease 
in the Q10/cholesterol ratio in older patients (6–16 years) were shown. The free 
carnitine blood level was within the normal range and averaged at 29.8 ± 2.6 μmol/l; 
however, the level was lower than that in the control group (44 ± 5.2 μmol/l, 
p < 0.05). A pronounced significant increase in the acylcarnitines/free carnitine 
ratio was determined—1.5 ± 0.05 (the normal range < 0.6).
Keywords: children, mitochondrial diseases, coenzyme Q10, carnitine, treatment
1. Introduction
Mitochondrial diseases are a large heterogeneous group of pathological condi-
tions caused by genetically determined defects in the mitochondria’s structure and 
function in the release of the energy of organic substances and its accumulation 
in the form of macroergic phosphate compounds by the generation of adenosine 
triphosphate [1]. These disorders can be due to mutations in mitochondrial DNA or 
due to mutations in nuclear DNA. Some mitochondrial diseases are rare. However, 
in general, mitochondrial encephalopathy is the most common neurometabolic 
disorder [2]. Defects in the respiratory chain and oxidative phosphorylation are the 
basis of the pathogenesis of these severe diseases.
Mitochondrial diseases have a wide range of clinical presentations with a gener-
ally poor prognosis: failure to thrive, encephalopathy, respiratory insufficiency, 
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hypotonia, ataxia, seizures, cardiac involvement, hepatopathy and nephropathy, 
sensorineural hearing loss, retinopathy, lesions of the basal ganglia, and others. The 
common laboratory signs are lactic acidosis, hypo- or hyperglycemia (diabetes), 
elevated creatine kinase and aminotransferases, and urine organic acid/amino acid 
abnormalities [3].
Current therapies are frequently inefficient and mostly palliative. The treat-
ment strategy for mitochondrial diseases is to improve the efficiency of biological 
processes in the respiratory chain and oxidative phosphorylation. Patients are 
prescribed complex treatment, including drugs that affect different stages of energy 
metabolism. This treatment approach shows a higher positive effect than mono-
therapy [4]. Coenzyme Q10 and L-carnitine are very important biologically active 
substances involved in energy metabolism. So, coenzyme Q10 and L-carnitine are 
often recommended for the treatment of mitochondrial diseases [5]. However, some 
authors acknowledge the lack of rationale behind these recommendations since the 
data from randomized clinical trials are still lacking.
2. Functions of CoQ10 and its biological role
Coenzyme Q10 is the most common ubiquinone in the human body. Its structure 
contains a quinoid ring and 10 isoprenyl groups. Coenzyme Q10 is structurally 
similar to vitamins E and K. Coenzyme Q10 exists in oxidized (ubiquinone) and 
reduced (ubiquinol) forms and is known to be a constituent of the biological mem-
branes [6]. Coenzyme Q10 is one of the main components of the electron transport 
chain of mitochondria. In the form of ubiquinone, it acts as an electron transporter 
from Complex I and Complex II to Complex III. In this process, the formation of the 
reduced form—ubiquinol—occurs. Ubiquinol is a powerful antioxidant, which has 
a protective effect on biological membranes, regulates their permeability, inhibits 
peroxidation of plasma lipoproteins, and provides a recovery of tocopherol activity 
[6, 7]. According to the recent data, coenzyme Q10 is reported to be involved in the 
regulation of some gene expression and inflammatory mediators, in particular, by 
influencing the transcription factor NFkappaB1; its participation in DNA replica-
tion and repair was shown [8, 9].
In mammals, the largest amount of coenzyme Q10 is found in the heart and 
skeletal muscles. In the peripheral blood, coenzyme Q10 is bound to lipoproteins, 
and its level is positively correlated with total cholesterol [10, 11].
Most of the body’s daily coenzyme Q10 requirement is derived from endogenous 
synthesis; small amounts of coenzyme Q10 are obtained from foods such as meat, 
fish, and nuts. Biosynthesis is a multi-step process, taking place on the inner mito-
chondrial membrane. Vitamins B2, B3, B6, B12, and C and folic and pantothenic 
acids are known to participate in the coenzyme Q10 biosynthetic pathway under the 
control of a dozen genes. The intensity of biosynthesis declines substantially with 
age [12, 13].
3. Coenzyme Q10 deficiency in disorders: the possibility of diagnosis
Primary coenzyme Q10 deficiency is due to a defect in its biosynthesis. These 
diseases form a separate group of mitochondrial diseases and are associated with 
mutations in multiple genes including PDSS1, PDSS2, CoQ2, CoQ6, CoQ9, and 
ADCK3. These diseases are characterized by a decrease in the level of coenzyme 
Q10 in tissues and in fibroblasts whereas the blood levels can be normal [11, 14, 15]. 
Secondary coenzyme deficiency with low plasma and tissue coenzyme Q10 levels 
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can occur in patients taking anticancer agents and statins. The hypocholesterolemic 
effect of statins is due to the inhibition of 3-hydroxy-3-methylglutaryl-COA reduc-
tase and a disruption of the synthesis of mevalonic acid, which is one of the precur-
sors of not only cholesterol but also ubiquinone. Approximately a half of patients 
receiving statins show a decrease in coenzyme Q10 in the muscle tissue; myalgia 
and myoglobinuria may also be observed [16, 17].
Secondary coenzyme Q10 deficiency and low levels of coenzyme Q10 in plasma 
and tissues are found in certain diseases of older age (Parkinson’s and Alzheimer’s 
disease, atherosclerosis, diabetes mellitus, etc.) [13, 18, 19], in some hereditary dis-
eases, including inborn errors of metabolism— mevalonic aciduria, phenylketon-
uria, glutaric acidemia II, ataxia-oculomotor apraxia 1, and cardiofaciocutaneous 
syndrome [11, 20]. Coenzyme Q10 deficiency in mevalonic aciduria and in phenyl-
ketonuria can be explained by insufficient cholesterol production: the decrease in 
the activity of mevalonate kinase and the inhibition of 3-hydroxy-3-methylglutaryl-
COA reductase with high levels of phenylalanine, respectively. In phenylketonuria, 
ubiquinone deficiency may well be exogenous due to dietary restrictions such as 
avoidance of animal products [10].
A decrease in coenzyme Q10 was reported in the peripheral blood and 
muscles in some (20–40%) patients with mitochondrial pathology associated 
with mutations and depletion of mitochondrial DNA [21, 22]. Of interest, in 
children with myopathy due to other causes, there were no changes in the content 
of coenzyme Q10 in the muscles, except for the patients with Duchenne muscular 
dystrophy [23].
The coenzyme Q10 deficiency can be detected in biological fluids (plasma or 
serum), fibroblasts, and muscle tissue. However, the blood level of coenzyme Q10 is 
not considered as a reliable indicator of its state in the body. There is no clear corre-
lation between the levels of ubiquinone in plasma and muscle tissue. This parameter 
is influenced by the lipid intake from foods and the blood levels of cholesterol and 
low-density lipoproteins [7, 10, 11]. Therefore, the ratio of coenzyme Q10 to cho-
lesterol and low-density lipoproteins is proposed for clinical use. Apparently, the 
measurement of coenzyme Q10 in the peripheral blood mononuclear cells appears 
to be a promising detection method.
4.  Low blood level of coenzyme Q10 as a diagnostic marker of 
mitochondrial encephalomyopathy and the rationale for therapy
In the Research and Clinical Institute of Pediatrics, an examination of 16 
children (group 1) aged 1–16 years (average age 8.3 ± 1.5 years) with mitochondrial 
diseases was performed.
In nine children, the disease was caused by deletions or point mutations of 
mitochondrial DNA: Kearns-Sayre syndrome (common deletion of mitochondrial 
DNA) in three; mitochondrial encephalomyopathy with pyramidal-extrapyramidal 
syndrome (MTND1 mutation) in two; mitochondrial encephalomyopathy with 
cardiomyopathy (MTTK mutations) in two; mitochondrial myopathy, encephalop-
athy, lactic acidosis, and stroke-like episodes (MTTL1 mutation) in 1; and maternal 
inherited Leigh syndrome (MTND3 mutation) in 1.
Seven children were diagnosed with mitochondrial diseases of nuclear origin: 
leukoencephalopathy with brain stem and spinal cord involvement and lactate 
elevation (DARS2 mutations) in four and Leigh syndrome (SURF1 mutations) 
in three.
The comparison group (group 2) consisted of 13 children with neurodegenera-
tive diseases aged 1–15 years (mean age 6.4 ± 1.3 y): 6 children with neuronal ceroid 
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lipofuscinosis 2 (TPP1 mutations), 2 with sialidosis type 2 (NEU1 mutations), and 5 
with progressive ataxia not genetically confirmed. The control group (group 3) con-
sisted of 29 healthy children aged 1–16 years (mean age 7.4 ± 0.8 y) who underwent 
a routine examination at the health center (an informed consent of the parents was 
obtained) [24]. The ratio of boys:girls is 16:13. There was no statistically significant 
difference in the average age between the three groups.
A detailed work-up of the patients of the first two groups included clinical 
(pedigree, neurological, cardiological, and other examinations) examination and 
biochemical tests. In all children, the plasma level of coenzyme Q10 was determined 
by high-performance liquid chromatography with UV detection (chromatograph 
Shimadzu Nexera LC-30). The blood cholesterol level was determined photo-
metrically (analyzer Konelab Prime 60i), followed by the calculation of the coen-
zyme Q10/cholesterol ratio. The DNA diagnosis of diseases was carried out in the 
laboratory of inborn errors of metabolism of Research Centre for Medical Genetics 
(Moscow, Russia).
Statistical data processing was carried out by methods of variation statistics and 
correlation analysis (Statistica, Excel 7.0). Student’s t-test was used to assess the 
statistical significance of the data, and the differences were considered statistically 
significant at p < 0.05.
The blood levels of coenzyme Q10 in children with mitochondrial diseases 
(group 1) were 0.56 ± 0.05 μmol/l (Table 1) and did not differ from that in the 
control group but was significantly lower (p < 0.01) than that in children with 
neurodegenerative diseases (group 2). The blood level of coenzyme Q10 in children 
with neurodegenerative diseases was 1.53 ± 0.23 μmol/l and significantly exceeded 
that in healthy children (p < 0.01).
The blood cholesterol level in patients of the first and second groups was 
significantly higher than that in healthy children (p < 0.01). The ratio of coenzyme 
Q10/cholesterol was severely impaired compared with that in healthy children (see 
Table 1). This parameter was significantly decreased in patients with mitochondrial 
diseases (0.10 ± 0.01 vs. 0.19 ± 0.01, p < 0.001) but increased in those with neuro-
degenerative diseases (0.31 ± 0.04, p < 0.002).
For the subgroup analysis, children aged 1–5 and 6–16 years were analyzed 
separately within each group (Table 2). In healthy children (group 3), there were 
no age-related differences.
In the group of older patients with mitochondrial diseases, the blood level 
of coenzyme Q10 was significantly lower than that in the younger subgroup 
(p < 0.05) and was significantly different from its level in children in the second 
Groups of 
children
Levels in the blood
Coenzyme Q10, μmol/l Cholesterol, 
μmol/l
Coenzyme Q10/cholesterol
Group 1, n = 16 0.56 ± 0.05 5.7 ± 0.32 0.10 ± 0.01
Group 2, n = 13 1.53 ± 0.23 4.8 ± 0.31 0.31 ± 0.04








1-2p, 1-3p, and 2-3p - significance of differences between groups (1-2, 1-3, and 1-3)
Table 1. 
Coenzyme Q10 and cholesterol levels (M ± m) in the blood of the examined children.
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(p < 0.001) and third (p < 0.05) groups of the same age. In addition, older 
patients (6–16 years) tend to have lower cholesterol levels and lower coenzyme 
Q10/cholesterol ratios than younger patients (1–5 years). In the group of children 
with mitochondrial encephalomyopathies, there was a negative correlation 
between the blood level of coenzyme Q10 and cholesterol and the patient’s age 
(r = −0.54 and r = −0.48, respectively; p < 0.05). There were no differences in 
the studied parameters between children with mitochondrial diseases caused 
by mutations of mitochondrial (n = 9) and nuclear (n = 6) DNA. By age, these 
subgroups were not different.
In the group of children with neurodegenerative diseases, the opposite tendency 
was observed toward higher rates of coenzyme Q10, cholesterol, and their ratios in 
patients of the older subgroup (see Table 2); unreliability of differences seems to 
be associated with a small number of patients. A positive correlation between the 
blood levels of coenzyme Q10 and cholesterol (r = 0.66; p < 0.05) was established. 
These parameters correlated positively with the age of the patients (r = 0.37 and 
r = 0.41, respectively; p < 0.05).
To sum up, our study demonstrated that the average level of coenzyme Q10 in 
patients with mitochondrial diseases did not differ from that in healthy children. 
However, these patients had a higher cholesterol level and, as a result, a reduced 
ratio of coenzyme Q10/cholesterol. In patients of the older subgroup (6–16 years), 
the changes were more pronounced: significantly lower levels of coenzyme Q10 
and a tendency toward a lower Q10/cholesterol ratio than the younger subgroup 
(1–5 years).
In children with neurodegenerative diseases (not caused by primary mitochon-
drial dysfunction), the level of cholesterol (as well as in the first group) was higher 
than that in healthy children. Other test results differed considerably from those in 
patients with mitochondrial pathology. High blood level of coenzyme Q10 and an 




































Age 1–5 years, n = 15 0.64 ± 0.04 3.5 ± 0.16 0.19 ± 0.02
Age 6–16 years, n = 14 0.69 ± 0.07 3.6 ± 0.18 0.20 ± 0.02
*Significant difference from the older age subgroup; р < 0.05. 1-2p, 1-3p, and 2-3p - significance of differences between 
groups (1-2, 1-3, and 1-3)
Table 2. 
Coenzyme Q10 and cholesterol levels (M ± m) in the blood in children of different age subgroups.
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increase in the coenzyme Q10/cholesterol ratio were revealed, and these changes 
increased with age.
Due to a small sample size, the obtained data were considered as preliminary. 
Nevertheless, our results revealed a coenzyme Q10 deficiency in children with mito-
chondrial diseases and emphasized the difference in the pathogenesis of primary 
mitochondrial diseases and neurodegenerative diseases of non-mitochondrial ori-
gin. In both patient groups, the age-related aggravation of these changes was noted 
to correspond to a progressive disease course. The similarity of clinical manifesta-
tions underlies the difficulties in the differential diagnosis between mitochondrial 
encephalomyopathies and neurodegenerative diseases. The detection of the plasma 
coenzyme Q10 level can be helpful in the differential diagnosis between these 
conditions.
In addition, a low coenzyme Q10/cholesterol ratio and a tendency toward a 
decrease in the coenzyme Q10 levels with age suggest its insufficiency in patients 
with progressive mitochondrial encephalomyopathy. This provides a rationale for 
the use of coenzyme Q10 in the treatment of patients with mitochondrial diseases.
5. Functions of carnitine and its biological role
Carnitine (β-hydroxy-γ-trimethylaminobutyric acid) is a low molecular weight 
compound, which is crucial for energy metabolism in the human body. As an 
L-stereoisomer, carnitine is present in various tissues. Endogenous carnitine forma-
tion occurs in the liver, kidney, and brain cells through the transformation of the 
amino acids lysine and methionine, with a glycine involvement. Vitamins C, B6, and 
B3 and iron ions are the cofactors for carnitine biosynthesis. The biosynthesis steps 
are under the control of mitochondrial enzymes (trimethyl-lysine deoxygenase, 
3-OH-trimethyl-lysine aldolase, 4-trimethylaminobutanal dehydrogenase, butyr-
obetaine dioxygenase) [25]. However, biosynthesis provides only a part of carnitine 
daily requirements, and the main source of its intake is animal foods including red 
meat, fish, and dairy products. Carnitine absorption in the gastrointestinal tract, 
tubular reabsorption, and delivery to the tissue are provided by transport proteins, 
with OCTN2 being the main carnitine transporter. Carnitine is transported to the 
skeletal muscles and myocardium—these tissues contain the main reserves of carni-
tine, due to their high activity of lipid metabolism [26]. The importance of carnitine 
for the body is evidenced by its almost complete reabsorption in the renal tubules.
Studies have established the value of carnitine for the processes of biological oxi-
dation and maintenance of mitochondrial functions in the human body. Carnitine 
is crucial in conditions of a high energy consumption. These conditions such as 
intercurrent diseases, increased physical activity, starvation, etc. are characterized 
by increased catabolism. After depletion of carbohydrate reserves, lipids become 
the main sources of the ATP synthesis in the body.
One of the main vital functions of carnitine is bioenergetics. Carnitine is 
involved in lipid catabolism, providing its initial stages—an activation and a 
transfer of long-chain fatty acids from the cytoplasm through the outer and inner 
mitochondrial membranes to the mitochondrial matrix, thereby making them 
available for subsequent β-oxidation to form acetyl-CoA. In addition, fatty acid 
oxidation is the main pathway of ketogenesis, and ketone bodies are an additional 
energy substrate for peripheral tissues and the brain [26, 27].
The effect of carnitine on fat metabolism occurs through its participation in 
the cytoplasmic synthesis of fatty acids. Carnitine provides the reverse transfer of 
acetyl groups of mitochondrial acetyl-CoA through the mitochondrial membrane 
into the cytoplasm.
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An important function of carnitine is due to its ability to bind acyl radicals. 
Thus, carnitine regulates tissue energy metabolism, affecting the ratio of acyl-
CoA/free CoA in the mitochondria. Likewise, the detoxifying role of carnitine is 
achieved through binding of organic acid derivatives (intermediates in oxidative 
processes) and its excretion from the cell. These organic acid derivatives, accumu-
lating in the mitochondria and cytoplasm, have an adverse effect, by inhibiting the 
enzyme activity.
Carnitine appears to play an important role in the permeability of mitochondrial 
membranes. The protective impact of carnitine relies on the prevention of a nega-
tive membranotropic action of toxic agents, inhibitors of complexes of a mitochon-
drial respiratory chain (3-nitropropionic acid, methylphenylpyridine, and others), 
and inducers of apoptosis (long-chain fatty acid radicals). Carnitine supplementa-
tion in experimental animals prevents these disorders or significantly reduces their 
severity and prevents a degenerative damage to the nervous tissue [28–31].
In addition, a favorable impact of carnitine on the cytokine production and on 
vascular endothelium was revealed. Carnitine is capable of restoring endothelial 
function and preventing of vascular remodeling caused by a decrease in nitric 
oxide production [25, 32, 33]. Apparently, the carnitine functions require further 
research.
6. Carnitine deficiency in diseases
There are primary and secondary carnitine deficiencies. The primary deficiency 
is due to an autosomal recessive defect of the gene SLC22A5, which is expressed in 
the skeletal muscles, heart, and kidneys. The gene SLC22A5 encodes a transport 
protein OCTN2, the sodium-dependent organic cation transporter. The genetic 
defect disrupts the transport of carnitine into the tissues and reabsorption in the 
renal tubules. The clinical manifestations of the disease include cardiomyopathy, 
skeletal myopathy, fatty liver, and kidney dystrophy [34].
The causes of secondary carnitine deficiency are diverse and associated with an 
interruption of endogenous synthesis and disturbance of absorption from food and 
of retention in the body, as well as with an increased excretion through the kidneys 
or gastrointestinal tract [35]. The activity of endogenous carnitine biosynthesis 
depends on the function of the liver and kidneys. Biosynthesis decreases with 
malnutrition due to a protein deficiency. Carnitine removal is enhanced in stress, 
intercurrent diseases, and impaired renal tubular function. Low blood carnitine 
level is determined in children with epilepsy treated with valproate, in patients with 
heart failure, and in patients on hemodialysis [36–38].
Secondary insufficiency occurs in inborn errors of metabolism. In particular, 
secondary carnitine insufficiency is characteristic for a large group of hereditary 
diseases of organic and fatty acid metabolism. In these diseases, low levels of carni-
tine in the peripheral blood and tissues result from the accumulation of acylcarni-
tines and their enhanced renal excretion [34, 39].
7.  The carnitine insufficiency in children with mitochondrial 
encephalomyopathies
Some patients with mitochondrial diseases (about one-fourth patients) were 
reported to have a decrease in carnitine levels in the peripheral blood [40, 41]. Our 
study was designed to diagnose and treat carnitine insufficiency in patients with 
mitochondrial diseases; to achieve this, we analyzed the clinical parameters and 
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laboratory findings of 40 children aged 2–15 years: 25 with mitochondrial encepha-
lomyopathies (group 1) and 15 with congenital myopathies (group 2). Group 1 
consisted of 10 children with Kearns-Sayre syndrome (common deletion of mito-
chondrial DNA); 2 with mitochondrial myopathy, encephalopathy, lactic acidosis, 
and stroke-like episodes (MTTL1 mutation); 1 with myoclonic epilepsy associated 
with ragged-red fibers (MTTK mutation); 5 with leukoencephalopathy with brain 
stem and spinal cord involvement and lactate elevation (DARS2 mutations); 1 with 
Barth syndrome (TAZ mutation); 3 with Leigh syndrome (SURF1 mutations); and 3 
with POLG-related diseases (mitochondrial recessive ataxia syndrome in 2 and auto-
somal recessive progressive external ophthalmoplegia in 1). Group 2 consisted of 10 
children with central core disease and 5 with minicore myopathy. The control group 
included 10 children without mitochondrial diseases or congenital myopathies, who 
attended the clinic.
The clinical examination included pedigree, neurological, cardiological, and 
other examinations. In all children, acid–base balance of the blood and the level of 
lactic and pyruvic acids were determined. The level of L-carnitine—total carnitine, 
free carnitine (C0), and acylcarnitines (AC)—in dry blood spots was measured by 
chromatography-mass spectrometry (Agilent 6410 QQQ , USA). As an additional 
parameter of a possible carnitine insufficiency, the ratio AC/C0 was calculated. 
The DNA diagnosis of mitochondrial diseases was carried out in the laboratory of 
inborn errors of metabolism of the Research Centre for Medical Genetics (Moscow, 
Russia). Structural myopathy was diagnosed using a morphological study of muscle 
tissue (light and electronic microscopy, histochemical methods).
Statistical data processing was carried out by methods of variation statistics and 
correlation analysis (Statistica, Excel 7.0). Student’s t-test was used to assess the 
statistical significance of the data, and the differences were considered statistically 
significant at p < 0.05.
In children with mitochondrial diseases, the clinical presentations of the ner-
vous and muscular system involvement prevailed: fast fatigability, low exercise 
tolerance, muscle weakness and hypotension, and a development delay. Severe 
psychomotor retardation was noted in three children with Leigh syndrome. Most 
patients had ataxia, ophthalmoplegia, headaches and vomiting, and heart damage 
(atrioventricular blockade, cardiomyopathy). Some patients had a short stature, 
seizures, retinitis pigmentosa, a hearing loss, and an impaired liver function with a 
moderate increase in blood aspartate and alanine aminotransferase.
Compensated metabolic acidosis was detected in 12 of 25 children. Elevated 
blood lactate levels were noted within the range 2.9–6.7 mmol/l in 20 children 
(the normal range 1.0–1.7 mmol/l). In 11 patients, the pyruvate level was elevated 
(0.19–0.39 mmol/l, norm 0.09–0.12 μmol/l).
In children with mitochondrial diseases, the total carnitine blood levels 
(Figure 1) ranged from 39.1 to 95.3 μmol/l, averaging (M ± m) 75.8 ± 6.2 μmol/l 
(in the control group—from 41.1 to 119.9 μmol/l; 73.7 ± 9.7 μmol/l). There was a 
negative correlation between the total carnitine and lactate in the peripheral blood 
of patients with mitochondrial diseases (r = −0.65; p < 0.05).
The free carnitine blood level was within the normal range (19–60 μmol/l) and 
averaged at 29.8 ± 2.6 μmol/l; however, the level was lower than that in the control 
group (44 ± 5.2 μmol/l, p < 0.05). In six patients, the free carnitine blood level was 
at the lower limit of the normal range, not exceeding 25 μmol/l.
The average acylcarnitine level was 44.5 ± 3.7 μmol/l (see Figure 1); 87% of 
acylcarnitines were represented by acetylcarnitine (C2). Acetylcarnitine level was 
38.7 ± 3.9 μmol/l (higher than that in control group; p < 0.05); its level in four 
children went beyond the limit of the normal range (56.3, 60.2, 64.5, 65.7 μmol/l at a 
rate of up to 50 μmol/l).
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About a half (13) of the patients had elevated levels of other acylcarnitines: 
methylmalonyl-(C4DC), tiglyl-(C5: 1), glutaryl-(C5DC), hydroxybutyryl-(C4OH), 
hydroxyisovaleryl-(C5OH), and hexanoyl-(C6); there was an increase in the blood 
levels of alanine, glycine, and leucine. These metabolic changes are likely to be 
associated with the activation of ketogenesis, an impaired metabolism of lactate and 
pyruvate in mitochondrial diseases.
On average, the proportion of free carnitine was merely 39% of the total blood 
carnitine (the normal range is 70–80%). The proportion of acylcarnitines was 61%, 
significantly exceeding that of healthy subjects (20–30%).
The ratio of acylcarnitines and free carnitine AC/C0 was markedly increased 
to 1.3–1.8, reaching an average of 1.5 ± 0.05 (the normal range < 0.6). The increase 
in this ratio suggests the relative insufficiency of free carnitine and confirms the 
accumulation of esterified forms in the total carnitine pool.
In the patients with congenital myopathies, the clinical presentations predomi-
nantly included myopathic manifestations, impaired motor development, and 
increased fatigue. Moderately elevated blood lactate levels were found in eight 
children (1.9–2.8 mmol/l, the normal range 1.0–1.7 mmol/l). In 10 patients, the 
pyruvate level was increased (0.17–0.5 mmol/l, norm 0.09–0.12 mmol/l).
The total carnitine blood levels in children ranged from 46.7 to 106.1 μmol/l, 
averaging at (M ± m) 71.4 ± 3.5 μmol/l. There was no difference in total carnitine 
level between the patients with congenital myopathies and the control group.
The mean free carnitine level of 35.0 ± 1.9 μmol/l was within the normal 
range, but it was lower than that in the control group (p < 0.05). In two children 
with structural myopathy, free carnitine level was at the lower limit of the 
normal range.
The mean level of acylcarnitines was normal (36.9 ± 2.4 μmol/l). Likewise, the 
level of acetylcarnitine is not elevated. Of note, levels of other acylcarnitines were 
moderately elevated in three patients.
The proportion of free carnitine in the total carnitine was reduced—49% (the 
normal range 70–80%). The proportion of the esterified forms accounted for 51% 
of the total carnitine, which significantly exceeded the corresponding values of 
healthy individuals (20–30%). The ratio of acylcarnitines and free carnitine AC/C0 
was increased to 0.9–1.7, averaging at 1.1 ± 0.08 (norm <0.6), which was consistent 
with carnitine insufficiency. In the control group of conditionally healthy children, 
Figure 1. 
Comparison of carnitine levels (μmol/l) in dry blood spots in children of three groups. * significant difference 
(p < 0.05) with groups 2 and 3. ** significant difference (p < 0.05) with group 3.
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the ratio of AC/C0 was 0.66 ± 0.03 and was significantly different from that in 
groups 1 and 2 (p < 0.01).
The comparison of the carnitine parameters in patients with mitochondrial 
encephalomyopathies and congenital myopathies showed that in mitochondrial 
diseases, carnitine deficiency was more pronounced. Although the levels of acyl-
carnitines, free and total carnitine, were not significantly different, in the group of 
children with mitochondrial diseases, there was a tendency for an accumulation of 
bound carnitine and a lower level of free carnitine. Additionally, an acetylcarnitine 
level was significantly higher, and the impairment of total carnitine composition 
was more pronounced in children with mitochondrial diseases than in those with 
congenital myopathies. This was confirmed by a higher ratio of AC/C0 (1.5 ± 0.05 
vs. 1.1 ± 0.08; p < 0.01).
The detection of carnitine deficiency underscores the need for L-carnitine 
therapy. L-carnitine per os in a dose of 30–50 mg/kg/day (depending on age) was 
included in the complex of energy treatment (coenzyme Q10, succinates, vitamin 
B) of patients with mitochondrial diseases. Within 1 year, three courses of therapy 
(for 2 months) were prescribed with a period off treatment for 1–2 months.
After 10–12 months of a follow-up of 18 children, a distinct improvement in one 
third of the patients was demonstrated: a reduction of fatigue, an improvement of 
exercise tolerance, and a reduction in the frequency of headache and nausea attacks. 
In one half cases, a stabilization with minimal positive dynamics was observed. These 
15 children showed a decrease in the blood lactate level to 1.4–2.3 mmol/l. At the 
same time, in three children with Leigh syndrome, despite the treatment, a moderate 
progression of the disease with a persistent lacticidemia was observed.
The total carnitine remained at the same level (70.5 ± 5.1 μmol/l); a tendency 
(p > 0.05) toward an increase in the free carnitine level (36.2 ± 2.9 μmol/l) and a 
decrease in the acylcarnitine level (34.3 ± 4.1 μmol/l), including acetylcarnitine, was 
noted. A significant improvement in the AC/C0 ratio was revealed—a decrease to 
0.9 (p < 0.001); the proportion of free carnitine in total carnitine increased signifi-
cantly to 52% (p < 0.01). In general, the data indicate favorable changes: a reduction 
in carnitine deficiency, an improvement of its function, and a reduction in ketogen-
esis and in the severity of lactate metabolism disorders.
8. Conclusion
Coenzyme Q10 and carnitine are important components of energy metabolism 
that are involved in many biological processes in the human body. Our data suggest 
that there is an insufficiency of these compounds in patients with mitochondrial 
diseases. Our studies have not revealed the severe deficiency of these substances, 
while the evidence for a relative insufficiency were found. According to our labora-
tory data, coenzyme Q10 deficiency is manifested by a significantly low ratio of 
coenzyme Q10/cholesterol. Lower absolute level of coenzyme Q10 and tendency 
toward a more pronounced decrease in the Q10/cholesterol ratio in older patients 
(6–16 years), in our opinion, are consistent with the progressive course of mito-
chondrial pathology.
Carnitine deficiency is manifested by a tendency toward a decrease in the free 
carnitine blood level, a pronounced decrease in its proportion in total carnitine, and 
a significant increase in the ratio of bound and free carnitines.
The coenzyme Q10 and free carnitine insufficiency certainly adversely affects 
the course of the disease. The causes for these disorders remain unclear. Perhaps, 
defective mitochondria are not able to provide adequate biosynthesis of coenzyme 
Q10. Depletion of free carnitine is likely to occur as a result of the activation of 
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conjugation of acyl radicals, which accumulate in the disorders of respiratory chain 
and oxidative phosphorylation.
Given a crucial role of carnitine and coenzyme in mitochondrial energy pro-
cesses, the insufficiency of these compounds should be treated. Clinical heteroge-
neity of mitochondrial diseases justifies further research in homogeneous patient 
groups in order to develop evidence-based recommendations and ensure higher 
treatment efficacy. Furthermore, a moderate carnitine deficiency in congenital 
structural myopathies provides indications for carnitine supplementation.
Author details
Ekaterina A. Nikolaeva1*, Ilgar S. Mamedov2 and Irina V. Zolkina2
1 Research and Clinical Institute of Pediatrics named after Yuri Veltischev, Pirogov 
Russian National Research Medical University, Russian Ministry of Health, Moscow, 
Russian Federation
2 LLC “Laboratory of Chromatographic Systems”, Moscow, Russian Federation
*Address all correspondence to: kate_nikolaeva09@mail.ru
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
108
Mitochondria and Brain Disorders
[1] Tucker EJ, Compton AG, Thorburn 
DR. Recent advances in the genetics 
of mitochondrial encephalopathies. 
Current Neurology and Neuroscience 
Reports. 2010;10(4):277-285
[2] Debray FG, Lambert M, Chevalier I, 
Robitaille Y, Decarie JC, Shoubridge EA, 
et al. Long-term outcome and clinical 
spectrum of 73 pediatric patients with 
mitochondrial diseases. Pediatrics. 
2007;119(4):722-733
[3] Kanungo S, Morton J, Neelakantan 
M, Ching K, Saeedian J, Goldstein A. 
Mitochondrial disorders. Annals of 
Translational Medicine. 2018;6(24):475
[4] Parikh S, Goldstein A, Koenig MK,  
Scaglia F, Enns GM, Saneto R, et al. 
Diagnosis and management of 
mitochondrial disease: A consensus 
statement from the mitochondrial 
medicine society. Genetics in Medicine. 
2015;17(9):689-701
[5] El-Hattab AW, Zarante AM, 
Almannai M, Scaglia F. Therapies for 
mitochondrial diseases and current 
clinical trials. Molecular Genetics and 
Metabolism. 2017;122(3):1-9
[6] Crane FL. Biochemical functions 
of coenzyme Q10. Journal of the 
American College of Nutrition. 
2001;20(6):591-598
[7] Molyneux SL, Yong JM, Florkowski 
CM, Lever M, George PM. Coenzyme 
Q10: Is there a clinical role and a case 
for measurement? Clinical Biochemist 
Reviews. 2008;29:71-82
[8] Schmelzer C, Lindner I, Rimbach G, 
Niklowitz P, Menke T, Döring F.  
Functions of coenzyme Q10 in 
inflammation and gene expression. 
BioFactors. 2008;32(1-4):179-183
[9] Zhai J, Bo Y, Lu Y, Liu C, Zhang L.  
Effects of coenzyme Q10 on markers 
of inflammation: A systematic review 
and meta-analysis. PLoS ONE. 
2017;12:e0170172
[10] Hargreaves IP. Coenzyme 
Q10 in phenylketonuria and 
mevalonic aciduria. Mitochondrion. 
2007;7(Suppl. 1):S175-S180
[11] Emmanuele V, López LC, Berardo A, 
Naini A, Tadesse S, Wen B, et al. 
Heterogeneity of coenzyme Q10 
deficiency: Patient study and literature 
review. Archives of Neurology. 
2012;69(8):978-983
[12] Quinzii CM, López LC, Von-Moltke 
J, Naini A, Krishna S, Schuelke M, et al. 
Respiratory chain dysfunction and 
oxidative stress correlate with severity 
of primary CoQ10 deficiency. The 
FASEB Journal. 2008;22(6):1874-1885
[13] Hernández-Camacho JD, Bernier M, 
López-Lluch G, Navas P. Coenzyme Q10 
supplementation in aging and disease. 
Frontiers in Physiology. 2018;9:44
[14] DiMauro S, Quinzii C, Hirano M.  
Mutations in coenzyme Q10 
biosynthetic genes. The Journal 
of Clinical Investigation. 
2007;117(3):587-589
[15] Malicdan MCV, Vilboux T, 
Ben-Zeev B, Guo J, Eliyahu A, Pode-
Shakked B, et al. A novel inborn error 
of the coenzyme Q10 biosynthesis 
pathway: Cerebellar ataxia and static 
encephalomyopathy due to COQ5 
C-Methyltransferase deficiency. Human 
Mutation. 2018;39(1):69-79
[16] Lamperti C, Naini AB, Lucchini V,  
Prelle A, Bresolin N, Moggio M, 
et al. Muscle coenzyme Q10 level in 
statin-related myopathy. Archives of 
Neurology. 2005;62:1709-1712
[17] Qu H, Guo M, Chai H, Wang W, Gao 
Z, Shi D. Effects of coenzyme Q10 on 
References
109
Coenzyme Q 10 and L-Carnitine Disturbances in Children with Mitochondrial Diseases
DOI: http://dx.doi.org/10.5772/intechopen.87950
statin-induced myopathy: An updated 
meta-analysis of randomized controlled 
trials. Journal of the American Heart 
Association. 2018;7(19):e009835
[18] DiNicolantonio JJ, Bhutani J, 
McCarty MF, O’Keefe JH. Coenzyme 
Q10 for the treatment of heart failure: 
A review of the literature. Open Heart. 
2015;2(1):e000326
[19] Mantle D, Hargreaves I. Coenzyme 
Q10 and degenerative disorders 
affecting longevity: An overview. 
Antioxidants (Basel). 2019;8(2):44
[20] Nikolaeva EA, Mamedov IS. 
Deficiency of coenzyme Q10 in 
children: Clinical and genetic variants, 
diagnosis and treatment. Rossiyskiy 
Vestnik Perinatologii i Pediatrii (Russian 
Bulletin of Perinatology and Pediatrics). 
2012;57(2):77-83. (In Russ.)
[21] Sacconi S, Trevisson E, Salviati L, 
Aymé S, Rigal O, Redondo AG, et al. 
Coenzyme Q10 is frequently reduced in 
muscle of patients with mitochondrial 
myopathy. Neuromuscular Disorders. 
2010;20:44-48
[22] Montero R, Grazina M, López-
Gallardo E, Montoya J, Briones P, 
Navarro-Sastre A, et al. Artuch R; 
coenzyme Q ₁₀ deficiency study 
group. Coenzyme Q ₁₀ deficiency 
in mitochondrial DNA depletion 
syndromes. Mitochondrion. 
2013;13(4):337-341
[23] Miles L, Miles MV, Tang PH, 
Horn PS, Wong BL, DeGrauw TJ, 
et al. Muscle coenzyme Q: A potential 
test for mitochondrial activity and 
redox status. Pediatric Neurology. 
2005;32(5):318-324
[24] Nikolaeva EA, Kharabadze MN, 
Zolkina IV, Kulagina TE, Vasina TN, 
Stavtseva SN, et al. Diagnostic value of 
blood coenzyme Q10 levels in children 
with mitochondrial diseases. Rossiyskiy 
Vestnik Perinatologii i Pediatrii (Russian 
Bulletin of Perinatology and Pediatrics). 
2015;60(5):71-75. (In Russ.)
[25] Sharma S, Black SM. Carnitine 
homeostasis, mitochondrial function, 
and cardiovascular disease. Drug 
Discovery Today: Disease Mechanisms. 
2009;6(1-4):e31-e39
[26] Das AM, Steuerwald U, Illsinger 
S. Inborn errors of energy metabolism 
associated with myopathies. Journal 
of Biomedicine & Biotechnology. 
2010;2010:340849
[27] Houten SM, Wanders RJA. A general 
introduction to the biochemistry of 
mitochondrial fatty acid β-oxidation. 
Journal of Inherited Metabolic Disease. 
2010;33(5):469-477
[28] Wang C, Sadovova N, Ali HK, 
Duhart HM, Fu X, Zou X, et al. 
L-carnitine protects neurons from 
1-methyl-4-phenylpyridinium-
induced neuronal apoptosis in rat 
forebrain culture. Neuroscience. 
2007;144(1):46-55
[29] Oyanagi E, Yano H, Kato Y, Fujita 
H, Utsumi K, Sasaki J. L-Carnitine 
suppresses oleic acid-induced 
membrane permeability transition of 
mitochondria. Cell Biochemistry and 
Function. 2008;26(7):778-786
[30] Zou X, Sadovova N, Patterson 
TA, Divine RL, Hotchkiss CE, Ali SF, 
et al. The effects of L-carnitine on the 
combination of, inhalation anesthetic-
induced developmental, neuronal 
apoptosis in the rat frontal cortex. 
Neuroscience. 2008;151(4):1053-1065
[31] Sue YM, Chou HC, Chang CC, 
Yang NJ, Chou Y, Juan SH. L-carnitine 
protects against carboplatin-mediated 
renal injury: AMPK- and PPARα-
dependent inactivation of NFAT3. PLoS 
One. 2014;9(8):e104079
[32] Bueno R, Alvarez de Sotomayor M, 
Perez-Guerrero C, Gomez-Amores L, 
Mitochondria and Brain Disorders
110
Vazquez CM, Herrera MD. L-carnitine 
and propionyl-L-carnitine 
improve endothelial dysfunction 
in spontaneously hypertensive 
rats: Different participation of NO 
and COX-products. Life Sciences. 
2005;77(17):2082-2097
[33] Yousefinejad A, Siassi F, Javanbakht 
MH, Mohammadi H, Ghaedi E, Zarei 
M, et al. Effect of Genistein and 
L-carnitine and their combination 
on lipid profile and inflammatory 
cytokines in experimental Nephrotic 
syndrome. Reports of Biochemistry and 
Molecular Biology. 2018;7(1):1-8
[34] Longo N, Frigeni M, Pasquali M.  
Carnitine transport and fatty acid 
oxidation. Biochimica et Biophysica 
Acta. 2016;1863(10):2422-2435
[35] Buist NR. Historical perspective on 
clinical trials of Carnitine in children 
and adults. Annals of Nutrition & 
Metabolism. 2016;68(Suppl 3):1-4
[36] Adeva-Andany MM, Calvo-
Castro I, Fernández-Fernández C, 
Donapetry-García C, Pedre-Piñeiro 
AM. Significance of l-carnitine 
for human health. IUBMB Life. 
2017;69(8):578-594
[37] El Mously S, Abdel Ghaffar H,  
Magdy R, Hamza S, Mansour M.  
Carnitine deficiency in epileptic 
children treated with a diversity of 
anti-epileptic regimens. Egyptian 
Journal of Neurology, Psychiatry and 
Neurosurgery. 2018;54(1):37
[38] Moreira da Silva Guimarães S, de 
Souza Cruz WM, de Souza Weigert G, 
Scalco FB, Colafranceschi AS, Ribeiro 
MG, et al. Decompensated chronic heart 
failure reduces plasma L-carnitine. 
Archives of Medical Research. 
2018;49(4):278-281
[39] Mamedov I, Zolkina I, Nikolaeva E, 
Glagovsky P, Sukhorukov V. Carnitine 
insufficiency in children with inborn 
errors of metabolism: Prevalence 
and treatment efficacy. Journal of 
Pediatric Endocrinology & Metabolism. 
2015;28(11-12):1299-1304
[40] Pancrudo J, Shanske S, Coku J,  
Lu J, Mardach R, Akman O, 
et al. Mitochondrial myopathy 
associated with a novel mutation in 
mtDNA. Neuromuscular Disorders. 
2007;17(8):651-654
[41] Haas RH, Chir B, Parikh S, 
Saneto RP, Wolf NI, Darin N, 
et al. The In-depth evaluation of 
suspected mitochondrial disease. 





Edited by Stavros Baloyannis
Edited by Stavros Baloyannis
The mitochondrion is a unique and ubiquitous organelle that contains its own genome, 
encoding essential proteins that are major components of the respiratory chain and 
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